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ABSTRACT 
 
The use of trastuzumab as standard treatment for HER2-positive breast carcinomas 
(BCs) had largely improved the clinical outcome of BCs patients. Unfortunately, many of 
them do not respond to the therapy and the pathological complete response (pCR) is 
achieved in only 50% of patients even in those with tumours classified as the most 
sensitive to trastuzumab (i.e. HER2-enriched and high immune infiltration).  
Given the relevance of the immune system in trastuzumab cytotoxicity and the 
immune regulatory functions of gut bacteria, this project aims at investigating the role of 
gut microbiota as extrinsic tumour factor that influences trastuzumab activity.  
We found that antibiotics abrogated trastuzumab benefit in FVB mice in a microbiota 
dependent manner. Vancomycin and streptomycin lowered the abundance of Clostridiales 
bacteria and compromised the recruitment of immune cells in tumour microenvironment. 
Similar results were obtained in a model of HER2-positive BC spontaneous tumorigenesis, 
but not in the BALB/c model. In the attempt to improve the response to trastuzumab in 
FVB mice, the role of lactic acid producing bacteria was explored and an improvement in 
the antitumor efficacy was observed.  
Patients treated with neoadjuvant trastuzumab, who achieved pCR (R) were 
characterized by higher abundance of Clostridiales bacteria and a lower representation of 
Bacteroidales as compared to those with residual disease (NR) at surgery. Transferring 
faecal material from R and NR into recipient mice recapitulated the response observed in 
patients indicating a causal role for commensal bacteria. Furthermore, the unsupervised 
analysis on patients gut microbiota composition identified two microbiota clusters that 
significantly discriminated patients according to trastuzumab benefit while no association 
between microbiota clusters and the HER2-enriched PAM50 molecular classification of 
tumour biopsies was observed. In conclusion, our data support the role of gut microbiota 
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composition in the therapeutic efficacy of trastuzumab independently of tumour intrinsic 
characteristics.  
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1.1 Breast Cancer 
Breast cancer (BC) represents the fourth cause of cancer mortality worldwide after 
lung, stomach and liver cancer and occupies the second place for incidence according to 
the International Agency for Cancer Research (IARC) {Bray, 2018}. In Italy, BC 
comprises the 29% of all tumours diagnosed in women, and also represents the first cause 
of cancer-related death in women independently from age. Although early diagnosis 
contributed to the decrease of mortality, the number of newly diagnosed cases are destined 
to increase and more than 53.000 new BC are expected for the next years in our country 
{AIOM, 2018}.  
1.1.1 Breast cancer classification 
BC is a complex heterogeneous disease and histopathological features and molecular 
characteristics are both considered for its classification {Russnes, 2017}. 
1.1.1.1 Histopathological classification of BC 
BCs are divided into invasive and non-invasive form according to the extension of 
the lesion. The non-invasive forms are characterized by abnormal proliferation of cells 
without the spreading into the surrounding normal breast tissue and are defined as: Ductal 
Carcinoma In Situ (DCIS) or Lobular Carcinoma In Situ (LCIS) depending on the location 
of cancerous lesion within the mammary gland {Lakhani, 2012}. 
The abnormal growth of cancer cells beyond the mammary duct (or lobule) define 
the invasive forms of BCs, which are classified into invasive breast carcinoma of “no 
special type” (NST) or “special subtype”. The invasive BCs of NST are the most common 
type of BCs and comprise all tumours without specific features of differentiation (75% of 
all BCs). BCs of special subtype include the invasive lobular carcinomas, tubular, 
cribriform, metaplastic, apocrine, mucinous, papillary and micropapillary carcinomas as 
well as medullary, neuroendocrine and adeno-cystic carcinomas {Lakhani, 2012}. 
13 
 
The histologic grade and the TNM staging system are used to evaluate the severity of 
the disease at diagnosis. The grading system {Elston, 1991} is based on the frequencies of 
tubule formation, mitotic cell number and nuclear pleomorphism and divides tumours 
according to a score that ranges from 1 to 3: Grade 1 (G1), well differentiated carcinomas; 
Grade 2 (G2), moderately differentiated carcinomas; Grade 3 (G3), poorly differentiated 
carcinomas. In the TNM tumour staging, the diameter of the nodules is indicated with T 
(0-4), with T1 that are tumours lower in size than 2 cm, T2 between 2-5 cm, T3 bigger than 
5 cm and T4 is used for tumour lesions that invaded adjacent vital organs. The spreading of 
the disease to the lymph nodes is displayed by N (0-3), and the presence of distant site 
metastasis with M (0-1) {Giuliano, 2017}. 
In addition to pathological feature, the analysis of molecular biomarkers are used in 
the routine clinical management of invasive BCs: oestrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 are evaluated 
by immunohistochemistry. The first three biomarkers represent the target of effective 
therapies used in the clinical practice {Marchiò, 2017 b} and they also predict the response 
to treatment. The expression of oestrogen receptor (ER) and the progesterone receptor (PR) 
predicts the efficacy of hormonal therapy {Hammond, 2010}, ER is expressed in almost 
70% of BCs while 60-65% of BCs are positive to PR {Lakhani, 2012}. 
The HER2 receptor is overexpressed in about 10-15% of BC and the US Food and 
Drug Administration (FDA)-approved Dako HerceptTest kit is used to evaluate its 
expression by IHC. The samples are scored according to the circumferential membrane 
staining, the intensity, and the frequencies of stained cells {Wolff, 2013}. Negative 
tumours comprise those scored as 0 (no staining) or 1+ (incomplete/faint staining on the 
membrane in ≤ 10% of the cells). Positive tumours are scored 3+ (complete circumferential 
membrane staining, intense and in >10% of the cells. Tumours with score 2+ and 
characterized by a weak to moderate membrane staining in >10% of tumour cells, are 
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define equivocal {Wolff, 2018} (Fig. 1.1 A). In equivocal tumours, the IHC staining is 
combined with fluorescence or chromogenic in situ hybridization (FISH and CISH, 
respectively), to determine the copy number of the ERBB2 gene (encoding the HER2 
protein). According the updated guideline of the American Society of Clinical Oncology 
and College of American Pathologists (ASCO/CAP) {Wolff, 2018}, the evaluation of 
ERBB2 amplification comprise the use of a dual-probe system: one directed against ERBB2 
gene and one that binds to the centromere of chromosome 17 (Chromosome enumeration 
probe 17, CEP17). Tumours are considered positive for IHS if the dual-probe 
HER2/CEP17 ratio is ≥2 with an average HER2 copy number < or ≥4. Furthermore, they 
are positive if the single-probe average HER2 copy number ≥6 signals/cell. For tumours 
with HER2 copy number signals ≥6 but with a HER2/CEP17 ratio <2 additional work-up 
is required and HER2 staining by IHC and ISH results should be evaluated together on 
section from the same tissue sample {Wolff, 2018} (Fig. 1.1 B-C). 
Figure 1.1 Representative images of HER2 testing in BC. A) IHC staining for the HER2 
expression at the membrane of tumours cells (adapted from {Kamangar}). B)  
Fluorescence in situ hybridization (FISH) of a case of HER2 gene-amplified BC: HER2 
amplification (red) and CEP17 (green) (adapted from {Zhao, 2017}). C) HER2 gene 
amplification by chromogenic in situ hybridization (CISH) (adapted from {Huret, 2013}). 
The last prognostic marker evaluated by IHC is the Ki67, an antigen expressed by 
cells in active proliferation with predictive and prognostic value in ER-positive BCs treated 
with neoadjuvant chemotherapy {Bertucci, 2013}.  
A B
C
Score: 0 Score: 1+
Score: 2+ Score: 3+
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1.1.1.2 Molecular classification of BC 
The evolution of genomic studies allowed the analysis of BC heterogeneity from a 
molecular point of view. Gene expression profile (GEP) data identified five “intrinsic 
subtypes” of BC {Perou, 2000 and Sorlie, 2001} classifying the breast tumours into 
Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like subtypes. Later in 
time an additional subgroup with characteristics similar to the Basal-like tumours was 
defined as the Claudin-low subtype {Herschkowitz, 2007}. The classification by intrinsic 
subtypes segregated BCs into two main clusters according to the ER status. The larger 
cluster comprise tumours positive for the expression of ER divided in Luminal A and 
Luminal B tumours. The ER negative BC comprised the HER2-enriched tumours and 
Basal-like subgroup including the Claudin-low tumours.  
Furthermore, following a large study performed by The Cancer Genome Atlas 
Project (TCGA) on more than 500 of primary BC, the molecular intrinsic subtypes were 
refined. The comprehensive analysis at the DNA level (considering methylation pattern, 
chromosomal copy-number variation and somatic/germline mutation), RNA (i.e. mRNA 
expression and miRNA) and protein showed the existence of four main BC subgroups that 
recapitulated the main intrinsic subtypes found by gene expression analysis (Fig. 1.2). 
Claudin-low and Normal-like subtypes were not confirmed by this study due to the low 
number of tumours with this particular phenotype {Curtis, 2012}. Besides providing the 
most valuable biological information on BCs, this classification has also prognostic value 
(Fig. 1.3). 
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Figure 1.2 Breast cancer intrinsic subtypes. Hierarchical clustering analysis of gene 
expression from samples of the publicly available dataset UNC {Prat, 2011}. 
 
Luminal A subtype 
Almost 50-60% of all BCs come under the Luminal A subtype. These tumours are 
characterized by a low histological grade and proliferation rate, and express genes typical 
for the breast luminal cells {Perou, 2000} as confirmed by the positivity to the luminal 
cells keratins 8/18. Luminal A tumours present high expression of genes activated by the 
ER transcription factor such as GATA3 and oestrogen-related LIV-1 {Sotiriou, 2003} and 
at the DNA level, low number of mutation or copy-number changes were found in these 
tumours {Curtis, 2012}. Good prognosis and lower rate of relapse are associated with 
Luminal A subtype and they also benefit the most from endocrine-therapy with hormonal 
aromatase inhibitors or selective oestrogen receptor inhibitors (i.e. tamoxifen) and selective 
ER regulators such as fulvestrant. 
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Luminal B subtype 
The Luminal B tumours comprise the 10-20% of BCs and present a more aggressive 
phenotype than Luminal A with a higher histological grade and proliferative index. Theses 
tumours express high levels of genes or protein related to proliferation and cell cycle (e.g. 
MKI67 and AURKA) but they have a lower expression of several luminal genes such as 
PGR and FOXA1, but not ESR1. Genomic mutation and copy-number changes are more 
frequent than in Luminal A {Curtis, 2012}. Several Luminal B tumours can also have 
overexpression or amplification of HER2. Despite the similar expression of ER, the 
Luminal B subtype has a worse prognosis than Luminal A, in addition it is associated with 
a partial response to the endocrine therapy but benefit from neoadjuvant chemotherapy 
{Eroles, 2012}. 
HER2-enriched subtype 
This subtype includes 15-20% of all BC subtypes that are characterized by the 
overexpression of the ERBB2 oncogene and several genes of the HER2-pathway or the 
HER2 amplicon at the 17q22.24 (e.g. GRB7) {Perou, 2000}. These tumours present 
intermediate expression of luminal-related genes such as ESR1 and PGR, and low 
expression of basal-related genes (e.g. KRT5 and FOXC1), while they have the highest 
number of mutations across the genome among all BC subtypes, in particular common 
mutations were found at DNA level in TP53 and PIK3CA {Curtis, 2012}. From a clinical 
point of view, HER2-enriched tumours are characterized by high proliferative index and 
high histological grade, in addition patients with HER2-enriched tumours have a poor 
prognosis although they benefit from neoadjuvant treatment with higher response rate than 
luminal tumours {Eroles, 2012}. 
Basal-like subtype 
The Basal-like subtype represents 10-20% of all BC, these tumours express genes 
typical of breast basal epithelial cells and stain positive for the basal keratins 5/6 and 17 
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together with EGFR at the IHC analysis. Basal tumours express high levels of 
proliferation-related genes (i.e. MKI67), intermediate HER2-realted genes and very low 
luminal genes expression. TP53 and PIK3CA are the most frequent mutated genes, and 
mutations in BRCA1 are usually associated with the Basal-like subtypes {Curtis, 2012}. 
High histological grade, large tumour size and lymph nodes involvement together with 
high mitotic index are peculiar for basal tumours. Due to the absence of ER, PGR and 
HER2 expression they are associated with TNBC although there is a certain grade of 
discrepancy between the two classifications {Slamon, 1987}. Similarly to the HER2-
enriched subgroup, they are characterized by worse prognosis but present high response 
rate to chemotherapy {Rouzier, 2015}. 
 
Figure 1.3 Clinical outcome of BCs according to intrinsic subtypes classification. Time 
to distant metastasis and overall survival curves of BC intrisinc subtypes with Claudin-low 
and Normal-like subtype excluded {Hoadley, 2014}. 
 
The relevance of tumours classification in predicting patients outcome, raised the 
need to develop a clinical-applicable test that could define intrinsic subtype at diagnosis. In 
2009, a predictor based on the expression of 50 genes was developed using microarray or 
real-time PCR (qRT-PCR) that was called PAM50 (Predictor Analysis of Microarray 50). 
This 50-gene classifier, beside reproducing with accuracy the tumour intrinsic subtypes it 
also maintained the prognostic and predictive value for the efficacy of anticancer treatment 
{Parker, 2009} observed in the previous studies.   
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Since 2011, the tumour intrinsic subtype-based approach was adopted for the 
recommendation of systemic adjuvant therapies in early BC (i.e. endocrine, chemotherapy 
and anti-HER2 treatment). However, due to the prohibitive costs of gene expression 
molecular assay, pathology-based surrogate definition of tumour intrinsic subtypes are 
commonly used in the clinical practice for the classification of tumours by the expression 
of the four biomarkers through IHC (i.e. ER, PR, HER2 and Ki67) {Goldhirsch, 2013a}:  
“Luminal A-like” ER-positive; PR-positive (≥20%); HER2-negative; Ki67 low (<14%). 
“Luminal B-like” (HER2-negative) ER-positive; PR low (or negative); HER2-negative;  
high Ki67 (>14%) or grade. 
                  (HER2-positive) ER-positive; HER2-overexpression/amplification; 
PR any; Ki67 any. 
“HER2-positive” ER and PR absence; HER2 overexpression/amplification 
“Triple negative” ER, PR, HER2-negative (80% of overlap between TNBC and  
the intrinsic Basal-like subtype). 
Although the clinicopathological surrogate is the most useful and applicable system 
to define the tumour subtype at the diagnosis, intrinsic biology identified by gene 
expression analysis provides clinical relevant information beyond the current pathology-
based classification {Prat, 2015}. 
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1.1.2 The HER2-positive breast cancer 
1.1.2.1 The human epidermal growth factor receptors family 
The HER2 receptor is a type I tyrosine kinase receptor (RTK), member of the 
ERBB/HER super family comprising: EGFR (HER1), HER3 and HER4. These receptors 
are compose by a large extracellular domain (or ectodomain, ECD) dedicated to the 
binding of the ligands {Schlessinger, 2002}, a transmembrane region and cytoplasmic TK 
domain. The ligand binding region of each family member is made of four different 
subdomains (I-IV): domain I and III are responsible for the binding of the ligand, while 
domain II guides the dimerization with other receptors {Ogiso, 2002}. The ECD is usually 
maintained in an inactive conformation with the dimerization subdomain blocked between 
domain III and IV, during the interaction with the ligand the conformation changes and the 
subdomain II is exposed externally activating the receptor. The cytoplasmic region consists 
of three components: a small intracellular juxta-membrane domain followed by the kinase 
domain, and a C-terminal tail which is phosphorylated upon activation and contains the 
docking site for downstream signalling molecules {Burgess, 2003}. The HER2 receptor 
differs from the other family members for its extracellular region that constitutively 
exposes the dimerization domain. This enables the interaction with the ligand-bound 
receptor or with another HER2 receptor without specific EGF-related ligand (i.e. hetero-/ 
homodimerization, respectively) {Garret, 2003}. 
The HER receptors bind to three different groups of ligands: the first group includes 
the epidermal growth factor (EGF) that, together with the transforming growth factor α 
(TGFα) and amphiregulin, binds specifically to HER1; the second group of ligands 
includes betacellulin, the heparin-binding EGF-like growth factor (HB-EGF) and 
epiregulin which bind to HER1 or HER4; the last group comprises the neuregulin growth 
factor (NGR), in particular NRG1-2 specific for HER3 and HER4, and NRG3-4, that bind 
exclusively HER4 {reviewed in Hynes, 2005}. HER2 is an orphan receptor without a 
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physical soluble ligand and it is the preferred dimerization partner for the other HER 
receptors {Graus-Porta, 1997}(Fig. 1.4). 
 
 
Figure 1.4 Members of the human epidermal growth factor receptor family and 
ligands. The structure of HER receptors consists in an extracellular ligand-binding 
domain, a transmebrane lipophilic domain and an intracellular tyrosine kinase (TK) 
domain. Ligand binding induces autophosphorilation and homo-/heterodimerization of the 
receptors leading to transphosphorilation with consequent activation of downstream 
signalling. No ligand for HER2 is known and homodimerization results in receptor 
activation. HER3 relies on heterodimerization for its transphosphorilation due to the 
absence of the TK domain. EGF (epidermal growth factor), TGFα (transforming growth 
factor alfa), AR (amphiregulin), BTC (betacellulin), HB-EGF (heparin-binding EGF), 
EPR, (epiregulin), NRGs (neuregulin) (adapted from {Hynes, 2005}). 
 
The HER family is important for the development and all receptors cooperate to 
activate multiple signalling pathways that regulate proliferation, apoptosis, invasion and 
metastasis, angiogenesis and cell differentiation. Under normal physiological conditions, 
spatial and temporal expression of their ligands controls the activation of HER receptors 
but dysregulation in HER signalling is implicated in a wide variety of solid tumours. 
Amplification of ERBB2 gene has been detected in a subset of BCs and it occurs in other 
human cancer (i.e. ovarian, gastro-oesophageal, bladder and salivary cancers) {Hynes, 
2005}. 
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1.1.2.2 HER2-positive breast cancer and treatment 
The HER2-positive BC subtype is characterized by aggressiveness and bad prognosis 
as the overexpression/amplification of the HER2 amplicon was correlated with a shorter 
time to relapse and a lower survival rate in women with advance BC that received only 
chemotherapy {Slamon, 1987}. The direct targeting of the overexpressed HER2 receptor 
represents the main strategy to inhibit its function in combination with chemotherapy. In 
1998, the US FDA approved the use of trastuzumab (Herceptin, Genetech, Inc) in 
metastatic BC patients based on the positive results obtained in a large phase III study in 
which trastuzumab combined with chemotherapy improved patients outcome {Slamon, 
2001}. Trastuzumab is a monoclonal antibody (mAb) that binds to the juxtamembrane 
region of HER2 and impairs the homo- or heterodimerization with other receptors resulting 
in the inhibition of intracellular pathway activation and tumour growth. Based on the 
positive results achieved in the metastatic setting, in 2006, trastuzumab was approved for 
the treatment of women with early stage HER2-positive BC reducing the risk of BC-
related death by nearly 33% {Romond, 2005} and improving event-free survival {Piccart-
Gebhart, 2005}. To date neoadjuvant and adjuvant treatment with trastuzumab, combined 
to chemotherapy, represent the standard of care in HER2-positive early BC {Balic, 2019}.  
Over the years, new drugs have been designed to target the HER2 receptor in 
combination with trastuzumab: new mAbs, like pertuzumab (Parjeta, Roche), or drug-
conjugated mAb (trastuzumab emtasine, T-DM1) that bind to the extracellular region have 
been introduced. While trastuzumab targets the juxtamembrane region (subdomain IV) of 
HER2,  the humanized mAb pertuzumab binds to the dimerization domain (subdomain II) 
preventing its activation by blocking the homo- and heterodimerization of HER2 with 
HER1 and HER3. A different strategy considers the use of TK inhibitors (TKI) such as 
lapatinib and neratinib to block the activation of HER2 intracellular signalling. Lapatinib 
(Tyverb, Novartis) is a reversible TKI specific for HER2 and HER1 that inhibits the TK 
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activation by competing with the ATP for the ATP-binding pocket on the intracellular 
domain of HER receptors. Differently, neratinib (Nerlynx, Puma Biotechnology, Inc.) is a 
pan-HER inhibitor that interacts covalently with a cysteine side chain in the TK domain of 
HER1, HER2, and HER4 {Di Modica, 2017}. 
1.1.2.3 Mechanisms of action of trastuzumab  
Trastuzumab was initially developed as an inhibitor of the HER2 activation to block 
its intracellular signalling. As for the other family members, HER2 activates two main 
intracellular pathway: the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3-kinase (PI3K) {Yarden, 2001} together with the signal transducer 
and activator of transcription protein (STATs), SRC {Ishizawar, 2004} and the mammalian 
target of rapamycin (mTOR), which is a serine/threonine kinase activated downstream of 
PI3K-AKT pathway {Bjornsti, 2004}. All these molecules are involved in the regulation of 
proliferation and cellular growth in cancer cells. Consequently to the HER2 inhibition by 
trastuzumab, the induction of the Rb-related protein p130 impairs the entrance of the cell 
in the S-phase {Sliwkowski, 1999} resulting in the cancer cell cycle arrests in the G1 
phase {Lane, HA}. The treatment with trastuzumab causes the ubiquitination of HER2 
protein inducing its endocytosis and degradation, reflected by the decrease of HER2 
expression on tumour cells surface observed in patients upon trastuzumab treatment 
{Burstein, 2003}. The binding of trastuzumab to the juxtamembrane domain, inhibits  the 
cleavage of the HER2 ECD operated by metalloproteinases resulting in a truncated 
membrane-associated fragment with conserved and improved kinase activity. High serum 
levels of HER2 ECD correlate with poor prognosis and decrease responsiveness to 
endocrine therapy {Leitzel, 1995} and chemotherapy {Colomer, 2000} in patients with 
advance BCs.  
Trastuzumab also exerts a cytotoxic activity by eliciting anti-cancer immune 
response. The Fc portion of the mAb is recognized by innate immune cells that express the 
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Fc receptor (FcγR) (e.g. natural killer (NK) cells, macrophages, neutrophils, and 
eosinophils) promoting an antibody-dependent cell-mediated cytotoxicity (ADCC) and 
phagocytosis (ADCP) against tumour cells (Fig. 1.5). Two relevant mechanisms of action 
for trastuzumab since its anti-tumour efficacy is lost in FcγR-deficient mice or upon FcγR 
inhibition in preclinical model {Clynes, 2000}. Furthermore, a loss-of-function 
polymorphism in the FcγR impairs trastuzumab efficacy in BC patients {Musolino, 2008 
and Tamura, 2011}.  
 
Figure 1.5 Mechanisms of action of trastuzumab. Trastuzumab inhibits the intracellular 
signalling downstream of HER2 homo/heterodimers and proteolytic cleavage of the HER2 
ECD. By binding to the extracellular portion of HER2 engages antibody-dependent cell-
mediated cytotoxicity (ADCC) and phagocytosis (ADCP) in innate immune cells (i.e., NK 
lymphocytes, macrophages, monocytes, and neutrophils) via the Fc portion of the antibody 
(adapted from {Di Modica, 2017}). 
 
The major role in ADCC is played by NK cells that, by inducing tumour cell 
cytolysis {Varchetta, 2007 and Di Modica, 2016}, also increase the availability of tumour 
antigens that are up taken by antigen presenting cells and presented via MHC class II. 
Moreover, the FcγR-mediated phagocytosis by dendritic cells (DCs) and macrophages 
enhances antigens presentation favouring  the development of tumour-specific T cell 
immunity. Thus, the priming of DCs (or antigen presenting cells in general, APC) 
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promotes the activation of CD8+ T cells and the polarization of CD4+ T cells towards a T 
helper 1 (Th1) phenotype. In parallel, trastuzumab-dependent NK-cell activation leads to 
cytokines secretion promoting the recruitment of myeloid and T cells within the tumour 
microenvironment {Muntasell, 2017}. By eliciting both innate and adaptive immunity, the 
anti-HER2 mAb exerts a vaccine-like effect that contributes to its clinical efficacy 
{Griguolo, 2019} (Fig. 1.6). 
 
Figure 1.6 Immunostimolatory activity of trastuzumab. Trastuzuamb elicits an 
antitumor immune response that involve the innate (i.e. natural killer cells, NK; DCs and 
macrophages) and adaptive (i.e. CD4+ and CD8 T lymphocytes) immunity. The binding of 
trastuzumab to HER2 induced ADCC, ADCP and complement-dependent cytotoxicity 
(CDC). Adaptive immune cells (i.e. CD4+ and CD8+ lymphocytes) are activated by 
dendritic cells that recognized opsonized tumour fragments and stimulate a cytotoxic anti-
tumour immunity. Antigens presented by MHC-II molecules activate CD4+ T-helper 
lymphocytes, which release interferon-γ (IFNγ), interleukin 2 (IL2) and prime CD8+ 
lymphocytes that can also recognize tumour antigens presented by MHC-I molecules 
directly {Bianchini, 2014}.  
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1.1.3 Efficacy of trastuzumab and predictive biomarkers 
1.1.3.1 (Neo)adjuvant treatment with trastuzumab 
The addition of trastuzumab to standard chemotherapy significantly improved the 
survival outcome of metastatic, advanced and early BCs. Based on the results of four large 
trials (HERA {Goldhirsch, 2013b}, FinHER {Joensuu, 2009}, NCCTG N9831, and the 
NSABP B-31 trials {Perez, 2011}) the treatment with trastuzumab is recommended for 1 
year in adjuvant setting {Goldhirsch, 2011}, demonstrating improvement in DFS and 
mortality in patients receiving the mAb {Dahabreh, 2008}. In neoadjuvant setting, the 
combination of trastuzumab and chemotherapy resulted in higher pathologic complete 
response (pCR) rates and improved DFS in patients treated with trastuzumab compared to 
chemotherapy alone in phase III trials {Budzar, 2007; Gianni, 2010; Untch, 2010}. Meta-
analysis on neoadjuvant studies {Valachis, 2011; von Minckwitz, 2011} concluded that the 
addition of trastuzumab improved the likelihood of achieving higher pCR rate. Of note, in 
the actual treatment of HER2-positive BC, the pCR in trastuzumab-treated patients is 
obtained at similar rate (46.8%) to that observed in clinical trials (40%) {Natoli, 2013} 
1.1.3.2 Predictive biomarkers of trastuzumab response 
Despite the improvement in the clinical outcome of HER2-positive BC patients, high 
grade of heterogeneity characterized the response to trastuzumab-based treatments, and, 
although some of the treated patients may even benefit exclusively from anti-HER2 agents 
without chemotherapy, many of them still do not completely respond to the treatment (i.e. 
less than 50% of pCR achieved in treated patients {Natoli, 2013}). For this reason, there is 
the need to identify accurate biomarkers that discriminate patients who actually benefit 
from trastuzumab treatment from who need further therapy. In this context, tumour 
intrinsic features and immune infiltrate have been largely investigate {Triulzi, 2016}. 
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Tumour intrinsic biomarkers 
The heterogeneity of the HER2-positive BCs is revealed when the PAM50 molecular 
classifier is applied within this subgroup of tumours, in fact, only 50% of them is classified 
as HER2-enriched {Prat, 2014b}. These tumours are characterized by high expression of 
HER2-related genes and low levels of luminal BC-associated gene and the HER2-enriched 
phenotype is associate with higher probability of pCR rate in patients receiving 
trastuzumab-based treatment than other clinical HER2-positive tumours as resulted from 
the analysis of the major clinical trials (NOAH {Prat, 2014}, CALGB 40601{Carey, 
2016}, NeoALTTO {Fumagalli, 2017}, and CHER-LOB {Dieci, 2016}). 
Coherently with the PAM50 classification, the mRNA expression levels of ERBB2 
and ESR1 genes predict the response to adjuvant trastuzumab, with high expression of 
ERBB2 and low ESR1 associated to trastuzumab benefit {Pogue-Geile, 2013}. In the 
neoadjuvant setting, the levels of ERBB2 and ESR1 were confirmed as the most important 
discriminant of pCR in the NeoALTTO {Fumagalli, 2017}, GeparQuattro {Denkert, 2013} 
and in the TRYPHAENA trials {Schneeweiss, 2014}. In addition, the new trastuzumab 
risk (TRAR) predictor, which is based on the expression levels of 41 genes related to 
ERBB2 and ESR1, is predictive of early relapse in adjuvant setting with patients classified 
as TRAR-low (high ERBB2 and low ESR1 mRNA levels) associated with better prognosis 
{Triulzi, 2015}. In the neoadjuvant setting, the TRAR signature predicts pCR in the 
NeoALTTO study {Di Cosimo, 2019} confirming the role of HER2 and ER expression in 
trastuzumab benefit.  
The higher sensitivity of HER2-enriched tumours to anti-HER2 agents was 
confirmed in the PAMELA trials {Llombart-Cussac, 2017}, in which higher percentage of 
pCR was observed in HER2-enriched tumours compared to other subtypes treated with 
neoadjuvant dual blockade with trastuzumab and lapatinib without chemotherapy. 
However, the fact that only half of HER2-enriched tumours (41%) achieved pCR, indicate 
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that further improvement are needed to accurately predict whether one will benefit from 
anti-HER2 treatment. 
Immune biomarkers  
Based on the relevance of immune cells in trastuzumab activity the predictive or 
prognostic potential of the tumour immune contexture was analysed. The tumour 
infiltrating leukocytes (TILs) include different cells type of mononuclear leukocytes such 
as macrophages, DCs, mast cells, NK cells, naïve and memory lymphocytes, B cells and 
effector T cells (comprising different subset of T cells such as Th1, Th2, Th17, regulatory 
T cells (T reg) and cytotoxic T cells). These immune population can be divided according 
to their role in cancer development and progression, CD8+ T cells, CD4+ Th1 and NK 
cells are generally considered to favour tumour suppressive responses, while CD4+ Th2, 
FOXP3+ Treg and immature DCs might have a pro-tumorigenic role {Salgado, 2015}. 
TILs are easily quantified through the hematoxylin/eosin staining of tumour biopsies 
considering both intratumoral and stromal leukocytes {Loi S, 2014}, BCs highly infiltrated 
(>50%  TILs) are defined as lymphocytes predominant BCs (LPBC). According to recent 
guidelines, TILs should be scored as continuous parameters to better represent the 
continuity of immune response with >60% of TILs set as cut off for highly infiltrated 
tumours {Salgado, 2015a; Dieci, 2018}. The prognostic value of TILs was described for 
the first time by Denkert and collaborators {Denkert, 2010} that demonstrated the 
prediction of pCR achievement by TILs abundance in BCs patients treated with 
neoadjuvant chemotherapy. In the HER2-positive BC the high infiltration of TILs was 
consistently associated with pCR in neoadjuvant trials such as NeoALTTO {Salgado, 
2015b} CHER-LOB {Dieci, 2016} and NeoSphere {Bianchini, 2015}.  
The immune status of patients can be also characterized by genomic signature. Perez 
and collaborators developed a signature consisting of 14 immune-related genes that 
discriminate tumours as immune response enriched (IRE) and non-enriched (NIRE) 
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{Perez, 2016}. Patients classified as IRE had tumours enriched in genes related to T and B 
cell responses, chemokine signalling and inflammation, these patients had a better DFS 
when treated with trastuzumab. In neoadjuvant setting, the expression of this signature and 
other interferon-related gene, along with STAT1 but not MHCI metagenes {Bianchini, 
2015}, highly correlated with pCR {Fumagalli, 2017}. Although the high predictive value 
of TILs and immune signatures in the neoadjuvant treatment, the prediction value of TILs 
in adjuvant setting is controversial and required further investigation{Loi, 2014; Perez, 
2016}. 
New emerging approaches to identify novel predictive biomarkers exploit the 
analysis of samples pre- and post-treatment, as for instance immune characterization in 
residual disease upon neoadjuvant treatment {Dieci, 2018}. In addition, the modulation of 
immune gene upon single-dose of trastuzumab revealed that the increment in the levels of 
MHCII metagenes {Triulzi, 2018b} and the expression of CD4+ T cell- related metagene 
{Varadan, 2016} were predictive of response to therapy. 
When the impact of tumour-related and immune-related features were analysed to 
understand the response to neoadjuvant chemotherapy plus anti-HER2 agents, immune 
signature added significant prediction of pCR beyond PAM50 classification {Dieci, 2016} 
supporting the need for the integration of such predictive biomarkers to increase the 
accuracy.  
1.1.3.3 Sources of tumour heterogeneity and immune infiltrate modulation 
Understanding which factors modulate immune infiltrate can help in the 
development of new treatment strategies and add further information to the already used  
predictive biomarkers. The most evident driver of heterogeneity in HER2+ BCs is the ER 
status, many immune parameters are inversely correlated with ER expression {Chung, 
2017}. Oestrogenic signalling interacts with immune activity, oestrogen might modulate 
susceptibility of cells to NK-mediated ADCC by up-modulating MHCI transcription 
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{Hamada, 1989}. The immunosuppressive activity of myeloid cells can be enhanced by 
oestrogen {Svoronos, 2017}, thus menopausal status of patients should be considered in 
the analysis of tumour immune microenvironment. The immune infiltrate is also dictated 
by high mutation burden corresponding to a greater amount of neoantigen found in HER2 
enriched tumours {reviewed in Griguolo, 2019} and infiltration of HER2-positive tumours 
by immune can also be associated with oncogene activation {Triulzi, 2018a}. 
Besides tumour molecular features and genetic (or epigenetic) alteration, life style, 
physical activity, sedentary behaviour, and diet have a determinant role in the development 
and progression of BC. While dietary fibre retard carcinogenesis increasing tumour 
infiltration by CD8+ cells, obesity (or metabolic obesity state) induces a systemic 
inflammatory status (i.e. increasing the levels of IL-6 and aromatase) but results in an 
immunosuppressive tumour microenvironment with BC from obese patients characterized 
by high levels of immunosuppressive macrophages {Howe, 2013}. Furthermore, dietary 
changes or antibiotic use may result in shift of the gut microbiota communities with a 
consequent impact on host immunity that may negatively affect the immune infiltrate of 
BC {Kroemer, 2015} (Fig. 1.7).  
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Figure 1.7 Factors that condition tumour immune microenvironment. Tumour 
molecular characteristics and external factors such as treatment history, obesity, gut 
microbiota and hormonal factors determine the abundance and functional state of the 
tumour immune infiltrate inducing an immunostimulatory or immunosuppressive tumour 
microenvironment {Kroemer, 2015}. 
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1.2 The gut microbiota 
The human microbiota comprises all the communities of commensal, symbiontic and 
pathogenic microorganisms that inhabit the body. The majority of them colonize the 
surface of the gut, skin and oral cavity and it is estimated that the human body is composed 
by 3x10
13
 eukaryotic cells and 3.9x10
13
 colonizing microorganisms {Sender, 2016}. 
Overall, the gut of each individual is colonized by more than 160 species of the 1200 that 
have been identified for a total biomass of 1.5-2 kg dominated by anaerobic Bacteria, 
Archaea, Eukarya and Viruses {HMP Consortium, 2012}. 
1.2.1 Methods to study the gut microbiota composition  
The possibility to study the gut microbiota characteristics and functions notably 
increased in parallel with the development of new techniques for its analysis. The 
strategies that can be used to study the microbiota are divided into culture-based or culture-
independent approaches. Bacterial culture allows cheap, but labour intensive, identification 
of bacterial species within the intestine, providing functional microbiome analyses. 
Although this methodology significantly improved in the last decade increasing the 
number of culturable bacteria from 30 to 70 % of total gut communities, it still gives a 
limited view of the microbial diversity restricted to those culturable microbiota members 
{Zuo, 2019; Ito, 2019}. 
A more defined ‘portrait’ of the intestinal microbiota, in terms of composition, has 
become possible through the advancement of culture-indipendent techniques comprising 
all those ‘omics’ disciplines, that consider the study of DNA, RNA, protein and 
metabolites: 
 Metagenomics (DNA): the study of the metagenome; it includes amplicon-based studies 
focused on marker genes such as 16S ribosomal RNA (16S rRNA), or shotgun 
sequencing analyses. 
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 Metatranscriptomics (RNA): the study of the metatranscriptome; it analyses the 
collective repertoire of mRNA within a biological sample 
 Proteomics (proteins) and metabolomics (metabolites): the study of metaproteome and 
metabolome; it examines protein and metabolites derived from the bacteria activity. 
The experimental questions and the type of sample in use should guide the researcher for 
the decision on which method to use. In the next future, methods for integrating all 
metagenomics and metabolomics information, that are now under development, will allow 
to have a more accurate ‘snapshot’ of the composition and function of the gut microbiota 
{Knight, 2018}. 
1.2.1.1 Microbiome metagenomic and metatranscriptomic analysis  
The majority of the studies investigating differences within the complex bacterial 
communities of the gut, relies on DNA- and RNA-based approaches that allow 
metagenomic taxonomy and functional assignment. 
Marker gene sequencing  
Sequencing represent the gold standard for taxonomic identification of bacteria and 
most of the studies are based on amplicon analyses in which a specific piece of DNA is 
amplified. In these analyses, PCR primers are used to amplify all the variants that occur 
between the highly conserved regions of a specific gene: the 16S ribosomal RNA (16S 
rRNA) for Bacteria and Archea and the internal transcribed spacer for Fungi. The 16S 
rRNA is a molecule of RNA contained in the 30S subunit of the bacterial ribosome 
designated to the initiation and extension of protein systhesis. It is highly conserved 
between bacterial species but it also contains variable regions that allow phylogenetic 
signals for taxonomic classification (Fig. 1.8). The taxonomic names are generally 
assigned by matching the DNA sequences to reference databases, three of the most 
characterized and frequently used databases are Greengenes {McDonald, 2012}, the 
Ribosomal Database Project (RDP) {Cole, 2014} and Silva {Pruesse, 2007}. This method 
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is suitable and works well for samples contaminated by host DNA, such as tissue and low-
biomass samples. In general, genus-level resolution is possible for most bacterial taxa, but, 
with 16S RNA gene sequencing, species resolution is difficult {Bokulich, 2018}. 
Figure 1.8 Ribosomal 16S RNA gene hypervariable 
regions. Nine hypervariable regions (V1–V9) are indicated 
on the  secondary structure of 16S rRNA. These regions are 
usually sequenced for taxonomic classification of the 
bacteria (adapted from {Erlandsen, 2005}). 
 
Whole metagenome ‘shotgun’ analysis  
Metagenomic sequencing considers all microbial genomes within a sample providing 
more detailed information and taxonomic resolution than single gene sequencing, although 
more expensive to prepare and difficult to analyse. ‘Shotgun sequencing’ fragments all the 
DNA from a sample into small pieces, sequences these fragments and tries to reconstitute 
the overlapping sequences into a view of the microbiome. Given adequate sequencing 
depth (the number of sequencing reads per sample), taxonomic resolution reaches species 
and even strain level {Scholz, 2016} by assemblying the whole microbial genome obtained 
from short DNA sequence reads thanks to the use of reference database {Mukherjee, 
2017}. Furthermore, with the metagenomic sequencing profile, the functional capability of 
an entire community can be reconstructed at gene level {Abubucker, 2012}. However, an 
important limitation to shotgun metagenomics is that all the DNA will be sequenced 
including the human DNA which constitutes a relevant source of contamination from the 
host.  
Metatranscriptome analysis  
Metatranscriptomics is different from both 16S and metagenomic sequencing, these 
two methods analyze the DNA within a sample regardless of cell viability or activity, 
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while metatranscriptomics offers a unique insight into the microbiota revealing the 
microbial responses to niche perturbation. This methology is very challenging since most 
bacterial transcript only last a few minutes {Laalami, 2013} and it is biased towards 
microorganisms with high rate of transcription {Giannoukos, 2012}. In addition, samples 
should be carefully preserved to avoid RNA degradation {Knight, 2018}. 
Metatranscriptomics and  metaproteomics, the analysys of the protein content in a sample 
by mass spectrometry, are two emerging technologies that allow a functional study of the 
microbiome. Despite the interesting potential of these disciplines, further improvements 
are required for the complex interpretation of the results which is also complicated by the 
fact that no correlation between mRNA expression and protein at the all-community level 
has been found in the few studies performed so far {Allaband, 2019}. 
The pros and cons of genomic analyses for evaluating microbial communities have been 
summarized in the Table 1.1. 
Table 1.1 Genomic approaches to study microbial communities (adapted from {Knight, 
2018}. 
Methods Pros Cons 
Marker gene (16S 
rRNA) analysis 
 Fast and inexpensive sample 
preparation and analysis 
 Useful in low-biomass and highly 
host-contaminated samples 
 Large public data sets for 
comparison 
 No live/dead or active discrimination 
 Amplification bias 
 Bias introduced by the choice of 
primers and variable regions 
 Resolution limited to genus level 
 No functional information 
Shotgun 
metagenome 
analysis 
 Microbial taxonomic and 
phylogenetic identity until strain 
resolution for known organisms 
 Relative abundance of bacteria 
functional gene 
 No PCR-related biases 
 Does not assume knowledge of 
microbial community 
 Expensive and laborious analyses 
 Contamination from host-derived 
DNA 
 No live/dead active discrimination 
 Possibility of assembly artifacts in 
population-averaged microbial 
genomes 
Metatranscrptome 
analysis 
 Estimation of actively transcribing 
microorganisms when paired with 
marker gene analysis 
 Capture of the dynamic intra-
individual variation and response to 
intervention and event exposure 
 Most expensive, laborious and 
complex sample preparation 
 Host mRNA contamination and need 
to remove rRNA 
 Careful sample collection and storage 
 Paired DNA sequencing to decouple 
transcription rate from bacterial 
abundance changes required 
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1.2.1.2 The study of the metabolome 
Metabolomics is emerging in the study of gut microbiota functions and activities, it 
includes the nonprotein small molecules that are a product of bacterial metabolisms. The 
metabolome can be studied through two different approaches that are defined targeted and 
untargeted metabolomics. In the fist case targeted metabolites are analysed according to 
the availability of reference standard while untargetd metabolomics allows for molecules 
discovery although it is less sensitive and quantitiative {Melnik, 2017}. To study the 
metabolome, gas chromatography or liquid chromatography are used to separate 
metabolites before mass spectrometry analysis, and it is important to consider  whether the 
molecules of interest will be capture or not when choosing which platform to use 
{Allaband, 2019}. Similarly to metatranscriptomics and metaproteomics, the study of the 
metabolome is emerging as a strategy to study the functions of the gut microbiota and it is 
usually coupled with 16S rRNA or shotgun sequencing in order to provide relevant 
information on both composition and activity of the intestinal bacteria.  
1.2.2 Composition of the gut microbiota 
The intestinal microbiota composition consists of a large number of microbial 
species. Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria and Verrucomicrobia 
are the dominant phyla that inhabit the gut with specific distribution varying along the 
gastrointestinal track (Fig. 1.9). The bacterial abundance increases from the proximal to the 
distal colon according to physiological variation of chemicals, pH, nutrients and mucus 
along the small intestine, caecum, and colon. The small intestine is structured in villi and 
crypts with a thin mucus layer that favours the colonization of adherent bacteria (e.g. 
segmented filamentous bacteria, SFB), whereas the colon presents an outer mucus layer 
that constitute the optimal habitat for mucin-degrading bacteria and a dense inner layer that 
is scarcely colonized except for restricted communities of bacteria. Lactobacillaceae and 
Enterobacteriaceae families are the most abundant in the small intestine while 
Bacteroidaceae, Prevotellaceae, Rikenellaceae, Lachnospiraceae and Ruminococcaceae 
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better tolerate the increment of pH from proximal to distal colon (Fig. 1.9) {Donaldson, 
2016}. The competition for similar environmental conditions and nutrients limits the 
outgrowth of bacteria favouring the equilibrium within and among bacterial species 
{Kommineni, 2015}. 
 
Figure 1.9 Gut microbiota composition in the human lower gastrointestinal tract. The 
digestive tract of human is inhabited by Bacteroidetes, Firmicutes, Actinobacteria, 
Proteobacteria and Verrucomicrobia whose distribution within the gut vary according to 
the different levels of oxygen, nutrients, pH and mucus layer (adapted from {Donaldson, 
2016}). 
 
1.2.3 Gut microbiota and immune system 
The intestinal microbiota regulates many local and systemic function of the host 
including the development and regulation of the immune system, especially with respect to 
the intestinal mucosal immunity where it favours the maturation of immune cells in 
Payer’s patches, mesenteric lymph nodes and the development of lymphoid follicles in the 
lamina propria {reviewed in Rooks, 2016}. Systemically, commensal bacteria regulate 
myelopoiesis in the bone marrow {Gorjifard, 2016} via circulating bacteria-derived 
molecules (lipopolysaccharide, LPS; peptidoglycan, or flagellin) and bacterial metabolites 
(e.g. short chain fatty acids, SCFAs). 
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1.2.3.1 Microbial messengers  
Microbial-derived signalling molecules 
The host immune cells discriminate pathogens from commensals recognizing 
conserved molecular patterns that are divided into microbe-associated molecular patterns 
(MAMPs, expressed by commensals bacteria), and pathogens-associated molecular 
patterns (PAMPs, typical of microbial pathogens). Bacteria presenting MAMPs such as 
LPS, peptidoglycan, flagellin or other structural components are recognized by pattern-
recognition receptors (PRRs) that include Toll-like receptors (TLRs), Nod-like receptors 
(NLRs) or RIG-1-like receptors (RLRs) that are express on epithelial and immune cells 
(i.e. monocytes, macrophages, NK cells and T lymphocytes) {reviewed in Medzhitov, 
2007; and Negi, 2019}. Although the majority of the interactions between gut bacteria and 
host occur at the level of the intestinal epithelial barrier {Coleman, 2018}, a wide variety 
of ligands for receptors expressed on immune cells can enter the circulatory system and 
signal at distance. These ligands include LPS, which signals through TLR4; caspase-
4/5/11, an intracellular sensors; and polysaccharide A from Bacteroides fragilis that binds 
to TLR2 {Fischbach, 2016}.  Regulation of host immune system also happens by shaping 
metabolic pathways of immune cells like the catabolism of tryptophan into the metabolite 
indole-3-aldehyde, a ligand of the aryl hydrocarbon receptor (AHR), which is an important 
immune modulator in innate lymphoid cells {Zelante, 2013}. 
Bile acids 
Bile acids are synthesized from cholesterol in the liver, and are released in the small 
intestine to enhance digestion and absorption of lipids and fat-soluble vitamins. Their 
reabsorption occurs in the ileum and colon, and only a small part (<5%) is secreted in 
faeces. Bacteria present in the gastrointestinal tract (including Bifidobacterium, 
Lactobacillus, Clostridium and Bacteroides) possess bile salt hydrolase enzymes (BSH) 
and initiate bile acid metabolisms by deconjugating the glycine or taurine from the sterol 
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core of the primary bile acid core (i.e. cholic acid and chenodeoxycolic acid). This 
mechanism prevents their reabsorption in the ileum and promotes their entrance in the 
large intestine where they undergo to microbiota-encoded conversion to secondary bile 
acids by bacteria that possess hydroxysteroid dehydrogenases {Ridlon, 2014}. 
Deconjugated primary and secondary bile acids have effects on the host and regulate 
immunity by signalling on the farnesoid X receptor (FXR)-α expressed by macrophages 
whose activation promotes anti-inflammatory response {Vavassori, 2009}. The 
proinflammatory response in monocytes and macrophages is also dampened by strong 
activation of TGR5 induced by secondary bile acids deoxycholic and lithocholic secondary 
bile acids {Perino, 2014; Pols, 2017} (Fig 1.10). 
 
Figure 1.10 Immune regulation by bile acids. Bile acids, produced in the liver, regulate 
barrier integrity and commensal community. They also exert immune regulatory function 
by controlling the proinflammatory response in immune cells {Blacher, 2017}. 
  
Short chain fatty acids (SCFAs) 
SCFAs represent the major fermentation products generated from bacterial 
fermentation of dietary fibre and comprise butyrate, propionate and acetate. In the human 
gastro intestinal tract the highest SCFAs concentration is found in colon at a molar ratio of 
approximately 60:20:20 for acetate:propionate:butyrate {reviewed in Parada Venegas, 
2019}. They are usually used by intestinal epithelial cells (IECs) as source of energy but 
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can also act as regulators of the immune system. These metabolites modulate different 
aspects of IECs and leukocyte development and function through activation of G protein-
coupled receptors (GPR43, GPR41, GPR109a and Olfr78), inhibition of histone 
deacetylases (HDAC) and stimulation of histone acetyltransferase (HAT) activity. These 
receptors show distinct patterns of expression and have been partially associated with the 
effects of the SCFAs on leukocytes and intestinal epithelial cells. SCFAs enter the cells 
through passive diffusion across the plasma membrane or via transporters such as Slc16a1 
and Slc5a8. (Fig. 1.11) {reviewed in Corrêa-Oliveira, 2016}. 
 
Figure 1.11 Modulation of intestinal and systemic immune cells by SCFAs. SCFAs are 
uptake by IECs through passive and active mechanisms (i.e GPR43, GPR41, GPR109a and 
Olfr78 or Slc16a1 and Slc5a8 transporters), when uptaken they can be used as a source of 
energy or exert immune regulatory function on DCs, macrophages, neutrophils and T 
lymphocytes {Blacher, 2017}. 
 
1.2.3.2 Regulation of host immunity  
Innate and adaptive immune populations are equally influenced by commensal 
bacteria in a context-/ cellular- and timing-dependent regulation. 
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 Innate immune cells 
The sensing of microbial molecules by TLRs and NLRs influences the transcriptional 
programming of innate immune cells regulating the proinflammatory response in myeloid 
{Chang, 2014} and lymphoid cells {Gury-BenAri, 2016}. The communication between 
microbiota and innate immune cells rely also on metabolites and secondary bile acids 
{Negi, 2019}, it can differ according to the cells type: innate lymphoid cells (ILCs) count 
on tryptophan metabolites while myeloid cells are sensitive to SCFAs {Chang, 2014}.  
Mononuclear phagocytes (i.e. monocytes, macrophages and dendritic cells) are 
important intermediates for the cross-talk between microbiota and host immune system. 
Monocytes, by sensing gut microbiota variation, regulate the trafficking of myeloid cells, 
in particular macrophages, in the intestinal mucosae {Sorg, 2010}. In addition, the activity 
of mucosal macrophages is regulated by butyrate towards an M2/tolerogenic phenotype 
{Scott, 2018} while gut derived metabolites trigger type I interferon signalling and 
potentiate their phagocytic activity in distal macrophages {Steed, 2017}. In the intestine, 
dendritic cells activity in promoting the downstream activation of T and B cells, is 
regulated by the signalling through TLR2 via MyD88, promoted by bacteria like 
Bacteroides fragilis {Surana, 2014} and by microbial product such as succinate, acetate 
and butyrate that bind respectively to the GPR91 or GPR43 {reviewed in Skelly, 2019}. 
SCFAs, in particular butyrate, seem to inhibit DCs maturation {Andrade-Oliveira, 2015} 
and reduce secretion of IL12p40 and IFNy {Liu, 2012} in vitro acting as inhibitor of 
HDACs activity via the SlC5a8 butyrate transporter {Gurav, 2015}. 
Different composition of gut microbiota is correlated with variation in the maturation 
of neutrophils {Danmlund, 2016} while their activity can be regulated by SCFAs via 
GPR43 activation and consequent modulation of pro- {Mirmonserf, 2012} and anti-
inflammatory {Vinolo, 2011} cytokines production.  
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Commensal microorganisms also regulate the maturation and the acquisition of the 
tissue-specific function of ILCs {Minton, 2019}, a family of innate immune cells with 
cytotoxic (NK cells) and non-cytotoxic function (ILC1, ILC2 and ILC3). 
Adaptive immune cells 
The adaptive immune system is influenced by the bacterial composition in the gut in 
many aspects. The microbiota is a strong inducer of proinflammatory Th17 and regulatory 
T cells in the intestine {Ohnmacht, 2015} and this is directly regulated by specific bacterial 
species such as the attachment of SFB to the IECs promoting the maturation of Th17 and 
Bacteroides fragilis that, through its polysaccharide A, influences the balance between Th1 
and Th2 cells and also stimulates Treg {Atarashi, 2013}. Evidence demonstrated the 
relevance of TLRs for the regulation of adaptive immune cells function and development. 
Through the interaction with TLRs, microbial stimuli induce the polarization of naïve T 
CD4+ cells into pro- or anti-inflammatory subset (such as Th1, Th2, Th17 and Treg) 
{Valentini, 2014} and induce CD8+ T cells activation {Tabiasco, 2006}. Furthermore, the 
SCFAs function as inhibitors of HDACs promotes the extra-thymic peripheral polarization 
of Treg {Arpaia, 2013} and plays a role in the balance between Th1 and Th17 polarization 
of T cells {Park, 2015}. 
The microbiome influences the accumulation of intestinal plasma cells that produce 
secretory IgA, while some species promotes the production of sIgA {Hapfelmeier, 2010} 
some members can degrade and inhibit their production by modulating plasma cells 
activity {Moon, 2015} and shaping mucosal immunity. 
1.2.4 Gut microbiota in health and disease 
The gut microbiota influences many local and systemic functions of the host 
including metabolism, inflammation and the development and regulation of most organ 
systems. The colonization of the gastrointestinal mucosae contributes to the intestinal 
homeostasis by strengthening the gut barrier and mucosal immunity. Furthermore, the gut 
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microbiota participates to the absorption of nutrient from diet contributing to the 6-10 % of 
daily calories intake derived from the digestion of plant carbohydrates and fibre otherwise 
indigestible by human {Bergman, 1990} and sustain the production of SCFAs and the 
synthesis of vitamins (e.g. B2; B12; K; and folic acid) molecules that can be exploited as 
messengers to intestinal mucosae and distant organs or tissues in the host (liver, adipose 
tissue, brain, cardiovascular system, lung, hormone and immune system) {Schroeder, 
2016}.  
In normal conditions, the colonization of pathogens is prevented by production of 
antimicrobial substances, occupation of ecological niches, nutrients competition and 
enhancement of IgA secretion by mucosal B cells, however significant changes in the gut 
microbiota composition (i.e. dysbiosis) can occur and negatively affect local and systemic 
homeostasis leading to a large variety of disorders (Fig. 1.12).  
 
Figure 1.12 Effects of gut microbiota on host physiology. The gut microbiota 
communicates with the host converting environmental signalling into metabolites which 
can signal locally or systemically to different organs and tissues in health and disease 
(adapted from {Schroeder, 2016 and Roy, 2017}). 
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Communication between commensals bacterial and host adipose tissue, mediated by 
FXR-α and TGR5 receptors signalling, regulates various aspects of thermogenesis 
{reviewed in Schroeder, 2016} in healthy individuals. Obesity and undernourishment are 
influenced by the intestinal microbiota and a reduced microbial diversity or a reduced 
activity of the axis growth hormone (GH)-insulin-like growth factor-1 (IGF-1) are 
associated to these metabolic conditions respectively {Schroeder, 2016}. In liver of obese 
individuals, the translocation of bacterial molecules trigger hepatotoxicity and progression 
of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) via 
the activation of TLRs signalling {Henao-Mejia, 2012}. Cardiovascular disease, and in 
particular the development of atherosclerosis, are associated to the gut microbiota 
composition due to the action of microbial enzymes such as trimethylamine (TMA) lyases 
which convert the choline and carnitine, derived from diet, into TMA further oxidised to 
trimethylamine oxide (TMAO), a toxic compound involved in the pathogenesis of 
atherosclerosis {Wang, 2011; Matsuzawa, 2019}. Several autoimmune diseases have been 
described to be influenced by commensal bacteria {Ho, 2015}, for instance type I diabetes 
or juvenile diabetes are characterized by imbalanced in the ratio between Bacteroidetes and 
Firmicutes and a reduced number of butyrate producing bacteria {de Goffau, 2014}. 
Similarly, in inflammatory bowel disease (IBD), a gastrointestinal disorder partly due to 
autoimmune deregulation and characterized by recurrent inflammation of the intestinal 
mucosal, dysbiosis and decreased microbial diversity, is linked to both the two phenotypes 
of IBD: Crohn’s disease {Hedin, 2014} and ulcerative colitis {Walujkar, 2014}. Other 
autoimmune condition such as allergies {West, 2014} and rheumatoid arthritis {Zhang, 
2015} have been linked to the gut microbiota status, in particular low microbial diversity 
has been observed to precede allergic disease {West, 2014}. 
Recently, evidence for gut microbiota influence on the development of the brain 
structure and response to stress has emerged. Intestinal microbes communicate with the 
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brain through microbial metabolites able to cross the blood brain barrier {Erny, 2015} or 
via the vagus nerve {Bravo, 2011; Li, 2018}. The microbiota-brain axis was described to 
have a role in both the development and treatment of psychiatric stress-related conditions 
such as depression and anxiety {Crumeyrolle-Arias, 2014}. Furthermore, association with 
an altered abundance of Firmicutes, Clostridiales and Bifidobacterium species, compared 
to control subjects, was found in children affected of autism, a developmental disorder 
marked by impaired interaction and restricted/repetitive behaviour, highlighting the 
possible connection between cognitive impairment and commensal bacteria{Meyer, 2011}.  
1.2.5 Gut microbiota, cancer and cancer therapy 
1.2.5.1 Bacteria-related tumorigenesis 
Certain bacteria species are causally linked or associated with cancer development: 
Helicobacter pylori is classified by the World Health Organization (WHO) as a class I 
carcinogens due to its genotoxic effects that promote gastric cancer {Ishaq, 2015}. 
Salmonella typhi and Helicobacter spp along with Fusobacterium nucleatum participate to 
the development of biliary {Mima, 2017} and colorectal cancer respectively {Kostic, 
2013}. The microbiota-related tumorigenesis can also be a secondary effect of local, or 
systemic, chronic inflammation caused by microbial metabolites such as SCFAs or 
secondary bile acids that influence the immune surveillance {Garcia-Castillo, 2016}. In 
liver, the inflammation consequent to the exposure, via the portal venous system, to 
intestinal bacterial components and metabolites can directly/indirectly lead to 
carcinogenesis {Yoshimoto, 2013; Ma, 2018}. In addition, the gut microbiota is thought to 
promote BCs through its role in steroid metabolism that increases the reabsorption of 
oestrogen, and its impact on energy metabolisms and obesity {Shapira, 2013}. 
1.2.5.2 Gut microbiota and cancer therapy 
The impact of gut microbiota on local and systemic antitumor immunity can also 
impact the outcome of anticancer therapy. So far, the influence of commensal bacteria on 
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the efficacy, as well as the toxicity, has been demonstrated for chemotherapy, immune 
checkpoint inhibitors, hematopoietic stem cell transplant (HSCT) and adoptive cell transfer 
(ACT), in preclinical and clinical studies (Table 1.2 and 1.3) {reviewed in McQuade 
2019}. 
Table 1.2 Preclinical evidence of the role of gut microbiota in anticancer therapies. 
Treatment 
Microbiota 
modification 
Tumour 
model 
Findings Refs 
Anti-PD-1 and/or 
anti-CTLA4  
ABX cocktail 
Fibrosarcoma 
(MCA-205), 
melanoma 
(RENCA), 
colon cancer 
(MC-38), 
Lewis lung 
carcinomas 
Antibiotic exposure decreased 
anticancer immune responses 
after ICI and compromised 
survival 
Routy, 2018a; 
Vètizou, 2015;  
Anti-PD-L1 
Different mice 
vendors 
Melanoma 
(B16) 
Microbiota composition 
influenced spontaneous 
antitumor immunity and anti-
PD-L1 treatment efficacy 
Sivan, 2015 
CpG-ODN anti-IL-
10R mAb or 
Oxaliplatin 
ABX cocktail 
Colon 
carcinoma 
(MC38), 
lymphoma 
(EL4) 
Microbiota impacted systemic 
innate immune responses upon 
treatment with anti-IL-10R plus 
CpG-ODN therapy or 
oxaliplatin, affecting the 
response to therapy. 
Iida, 2013 
Cyclophosphamide ABX cocktail 
Fibrosarcoma 
 (MCA-205) 
Preventing translocation of 
Enterococcus hirae to 
secondary lymphoid organs 
decreased T cell stimulation 
and the efficacy of 
chemotherapy 
Viaud, 2013; 
Daillere, 2016 
Allo-HSCT 
Single or 
combined 
antibiotics 
GVHD after 
allo-HSCT 
in C57Bl/6 
mice 
Combination of  piperacillin-
tazobactam or imipenem after 
allo-HSCT associated with 
shorter survival durations 
Shono, 2016 
Gemcitabine Ciprofloxacin 
Colon 
carcinoma 
(MC26) 
The gut microbiota contributed 
to chemotherapy resistance by 
altering drug metabolism 
Geller, 2017 
ACT from C57/Bl6 
mice 
Vancomycin, 
neomycin and 
metronidazole 
TC1 
Vancomycin stimulated 
CD8αDC and sustained 
systemic adoptively transferred 
antitumor T cells. Treatment 
with neomycin and 
metronidazole had no effect on 
ACT. 
Uribe-
Herranz,2018 
ABX, antibiotic cocktail; ACT, adoptive T cell transfer; allo-HSCT, allogeneic haematopoietic stem cell 
transplantation; CpG-ODN, CpG oligodeoxyribonucleotide; CTLA-4, cytotoxic T lymphocyte protein 4; GVHD, 
graft-versus-host disease; ICI, immune-checkpoint inhibitors; IL-10R , IL-10 receptor ; mAb, monoclonal 
antibody; MHC, major histocompatibility complex; PD-(L)1, programmed cell death protein (ligand)1; TC1, 
cervix and lung tumour cell line transformed by HPV E6/E7 viral oncogene {adapted from Routy, 2018b}. 
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Table 1.3 Clinical evidence of the role of gut microbiota in anticancer therapies. 
Treatment Patient cohort Findings Refs 
Immunotherapy     
Anti-PD-1 or 
anti-PD-L1 
249 patients with 
advanced-stage cancers 
(140 with NSCLC, 67 
with RCC, and 42 with 
UC) 
Antibiotic use associated with decreased 
response to ICI, Akkermansia 
muciniphila was found to be enriched in 
responders. 
Routy, 2018a 
Anti-PD-1 
43 patients with 
metastatic melanoma 
Better clinical outcome at 6 months and 
increased CD8+ T cells tumour infiltrate 
correlated with an enrichment of 
Faecalibacterium spp analysed in 
baseline faecal samples. 
Gopalakrishnan, 
2018 
Anti-PD-1 or anti-
CTLA4 
42 patients with 
metastatic melanoma 
Therapeutic benefit was correlated with a 
high abundance of Bifidobacterium 
longum, Collinsella aerofaciens, and 
Enterococcus faecium; Akkermansia 
muciniphila was present exclusively in 
responders. 
Matson, 2018 
Anti-PD-1 
(nivolumab) 
74 patients with advance-
stage NSCLC 
Prescription of antibiotics within 3 
months before or during nivolumab 
treatment did not affect PFS. 
Kaderbhai, 2017 
Anti-CTLA-4 
(ipilimumab) 
and/or anti-PD-1 
(nivolumab) 
Metastatic melanoma in 
two cohort (n=26 and 
n=39) 
Baseline gut microbiota composition 
correlated with clinical outcome 
Responders to ipilimumab plus 
nivolumab alone had faeces enriched for 
Fecalibacterium prausnitzii and Dorea 
formicigenerans, respectively. 
Chaput, 2017 
Anti-CTLA-4 
(ipilimumab) 
and/or anti-PD-
(L)1 (nivolumab/ 
pembrolizumab) 
39 melanoma patients 
ICI responders were enriched in 
Bacteroides caccae and had faeces with 
a high content of anacardic acid 
Frankel, 2017 
Anti-PD-1/ anti-
CTLA4 
(nivolumab/ 
ipilimumab) 
31 patients with 
metastatic RCC 
The use of antibiotics before ICI 
treatment was a predictor of poor 
response  
Ueda, 2019 
Anti-PD(L)-1 
and/or anti-
CTLA4 
196 cancer patients 
treated in routine clinical 
practice 
Prior antibiotic therapy to ICI treatment 
was associated to a worse response and 
OS 
Pinato, 2019 
Anti-PD1 
(nivolumab) 
37 chinese patients 
advanced NSCLC 
enrolled in two clinical 
trials 
The gut microbiota diversity correlated 
with the response to nivolmab. 
Responders exhibited enhanced memory 
T cell and NK cell signatures in 
peripheral blood cells 
Jin, 2019 
Chemotherapy    
Cyclophosphamide-
based 
chemotherapy 
800 patients with CLL 
and 122 patients with 
lymphoma 
The use of antibiotics against Gram-
positive bacteria during chemotherapy 
was associated with a reduced possibility 
to achieve objective response and with a 
shorter PFS. 
Galloway-pena, 
2016 
Standard surgery 
and adjuvant 
chemotherapy  
1069 CRC specimens 
Microbiota composition and presence of 
Fusobacterium nucleatum, correlated 
with clinical outcome, independent of 
standard cancer staging. 
Mima, 2016 
Myeloablative and 
non-myeloablative 
chemotherapy 
regimens 
500 patients with 
haematological 
malignancies undergoing 
allo-HSCT 
Antibiotic prophylaxis altered microbiota 
diversity and correlated with increased 
incidence of acute GVHD and worse OS. 
 
 
Routy, 2016 
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Myeloablative, 
reduced intensity 
and non-
myeloablative 
chemotherapy 
regimens 
Two cohort (n=541 and 
113) with haematological 
malignancies undergoing  
allo-HSCT 
Gut microbiota composition predicted 
clinical outcomes of allo-HSCT, 
Eubacterium limosum associated with 
decreased risk of relapse and 
progression, enrichment in Blautia spp. 
was associated with decreased GVHD-
related death. Antibiotic treatment was 
associated with under-representation of 
Blautia spp. 
Peled, 2017 
Allo-HSCT, allogeneic haematopoietic stem cell transplantation; AML , acute myeloid leukaemia; CLL , chronic 
lymphoblastic leukaemia; CRC, colorectal cancer ; CTLA-4, cytotoxic T lymphocyte protein 4; FMT, faecal 
microbial transplantation; GVHD, graft-versus-host disease; ICI, immune-checkpoint inhibitors; NSCLC, non-
small-cell lung cancer ; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed cell 
death 1 ligand 1; PFS, progression-free survival; RCC, renal cell carcinoma; UC, Urothelial carcinoma {adapted 
from Routy, 2018b}. 
Chemotherapy 
Chemotherapeutics and immunotherapeutics drugs are affected by the gut microbiota 
composition which modulates the activity, efficacy and toxicity of several chemotherapy 
agents. In experimental models, the anticancer activity of cyclophosphamide is mediated 
by the induction of Gram-positive bacteria translocation into secondary lymphoid organs 
eliciting a Th17 and Th1 immune response {Viaud, 2013}. In a different study, the gut 
microbiota contributed to the efficacy and toxicity of oxaliplatin by modulating the release 
of proinflammatory cytokines in myeloid cells, a mechanism that was impaired in 
antibiotic-treated mice and germ free animals {Iida, 2013}. In addition, Fusobacterium 
nucleatum, beside promoting the development of colon carcinoma, it also mediates 
resistance to therapy by activating autophagy via TLR4 and MyD88 pathway {Yu, 2017}.  
Besides the modulation of the antitumor immune response, the gut microbiota affects 
drug efficacy by regulating its metabolism. More than 40 drugs have been shown to be 
metabolized by the gut bacteria and, among them, the anticancer drugs methotrexate, 
gemcitabine and irinotecan are affected by the activity of bacterial enzymes 
{Spanogiannopoulos, 2016}. The efficacy of methotrexate, and antagonist of folic acid, is 
reduced by gut microbes due to its conversion from an active metabolite to a downstream 
metabolite with a reduced bioavailbilty {Haiser, 2013} by intestinal bacteria. Similarly, the 
efficacy of gemcitabine that is an antagonist of pyrimidines and acts by imparing the DNA 
synthesis, is negatively influenced by commensal bacteria. This drug functions within the 
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cell where it is activated and then transformed into the inactive metabolite difluoro-deoxy-
uridine by cytidine deaminase enzyme and finally degraded. It was observed that 
Gammaproteobacteria in the intestinal lumen or in tumours (i.e. pancreatic tumours) 
produce a long isoform of this enzyme that may contributes to gemcitabine resistance by 
increasing its degradation {Galler, 2017}. In a different scenario, the toxicity of irinotecan, 
(CPT-11), a topoisomerase I inhibitor, is increased by gut microbiota {Wallace, 2010}. 
Irinotecan is a prodrug activated (SN-38 active form) by the cleavage of the side chain by 
enzyme carboxylase in plasma, intestinal lumen mucosae, liver and tumour cells. It is then 
inactivated by the uridine 5’-diphospho-glucoronosyltransferase (SN-38G inactive from) 
and excreted into the intestinal lume with bile acids. However, during the transit through 
the intestinal lumen, the SN-38G isofom can be converted back into the active form by the 
enteric bacteria β-glucuronidase enzimes consequently increasing the intestinal toxicity of 
this drug {Wallace, 2010}. The modulation of gut microbiota is starting to be considered a 
new strategy to alleviate drug toxicity in patients, in the case of irinotecan the specific 
inibition of bacterial β-glucuronidase reduced severe diarrhoea in mice {Wallace 2010; 
Guthrie, 2017}. Furthermore, 5-fluorouracile-induced mucositis was ameliorated by using 
probiotics bacterial strain {Yeung, 2019} supporting the possibility to use the gut 
microbiota to fight chemotherapy-induced side effects. 
Immunotherapy and immune checkpoint blockade 
Preclinical studies showed the involvement of the gut microbiota in the response to 
immune checkpoint inhibitors such as anti-PD-(L)1 and anti-CTLA-4 mAbs and how 
modulation of intestinal ecology enhanced the therapeutic response {Vétizou, 2015; Sivan, 
2015}. The association between response to immunotherapy and commensal bacterial have 
also been described in patients across cancer type {McQuade, 2019}. Antibiotics 
assumption represented a negative prognostics factors for patients undergoing immune 
checkpoint inhibitors treatment {Routy, 2018a; Derosa, 2018} and also lower microbial 
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diversity or altered composition were associated to impaired response to therapy {Routy, 
2018a; Gopalakrishnan, 2018; Matson, 2018; Chaput, 2017; Frankel, 2017}. In the case of 
anti-CTLA4 therapy, the baseline differences in the gut microbiota composition associated, 
in multiple cohorts, with the possibility to develop immune-related adverse event, in 
particular colitis {Chaput, 2017; Dubin, 2016}. 
Other anticancer treatments 
The gut microbiota has a role in cancer therapies other than chemotherapy and 
immunotherapy. ACT is a form of immunotherapy whereby activated immune cells (T cell 
or NK cells) are transferred into the host to directly attack the tumour. The modulation of 
the gut microbiota by vancomycin has been shown to sustain transferred T cells in an IL-
12 dependent manner {Uribe-Herranz, 2018}. The broad spectrum antibiotics that are used 
in the setting of HSCT can induce a pronounced dysbiosis that impaires the gut integrity: 
the loss of beneficial bacteria (e.g. Faecalibacterium, Ruminococcus, Lactobacillus, and 
Blautia) have been associated with severe graft versus host disease and transplant related 
mortality in patients {Andermann, 2016;  Mathewson, 2016}. 
Similar to other cancer therapies that induce immunogenic cell death, radiotherapy 
causing cell death promotes systemic inflammation. The gut microbiota has been 
demonstrated to have a role in both response to therapy {Colbert, 2017} and  radiotherapy-
induced toxicity {Crawford, 2005}. 
Overall, two different aspects of the gut microbiota contribution to the therapeutic 
efficacy of anticancer treatments have emerged: on one hand, treatment-induced damages 
of the intestinal epithelial barrier allow translocation of bacteria from intestinal lumen to 
secondary lymphoid organs exerting an adjuvant effect on immune cells sustaining their 
activation against cancer. On the other hand, local intestinal microbiota provides tonic 
signals that prime immune cells creating conditions for an effective response to therapy 
{Gorjifard, 2016} (Fig. 1.13). 
51 
 
 
Figure 1.13 Impact of commensal bacteria on anticancer therapies. (1-3) Adjuvant 
effect of the gut microbiota in treatments that cause damages in the intestinal barrier 
allowing for bacteria translocation and stimulation of myeloid cells. (4-6) Priming effect of 
the gut microbiota to cancer therapy, tonic signals from the intestinal ecosystem shape host 
immunity and impact the response to therapy {Gorjifard, 2016}. 
 
1.2.5.3 Gut microbiota: biomarker or new treatment strategy? 
Microbiota  as biomarker 
Studies in preclinical models and human cohorts showed that the diversity and the 
composition of gut microbiota are associated with therapeutic efficacy in different forms of 
cancer (Table 1.1 and 1.2). This evidence sustains the potential use of gut microbiota as 
response biomarker to be considered alongside other biomarkers already in use. To date the 
potential use of gut microbiota signature has been described by Dr. Wargo’s group 
{Gopalakrishnan, 2018}: in this study, high basal abundance of Clostridiales and low 
abundance of Bacteroidales characterized responsive melanoma patients under anti-PD-1 
treatment. The profiling of gut, tumours, and other microbiota is now being integrated into 
the design of clinical trials for several type of cancer therapies but standardization of 
sample collection, methods used to sequence the samples (16S rRNA sequencing, 
metagenomics, metatrascriptomics and metabolomics profiling), and analysis pipelines 
represent relevant source of variability among institutions and common guidelines will be 
required to advance the biomarkers research. Generally, the composition of microbiota will 
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be considered as a complementary prognostic or predictive biomarker to be integrated with 
other known correlates of clinical outcome. 
Microbiota  as therapeutic intervention 
The evidence from preclinical models that modulation of intestinal microbiota can 
enhance therapeutic response to immunotherapy (i.e. Bifidobacterium {Sivan, 2015} 
Akkermansia muciniphila {Routy, 2018a}) and chemotherapy (i.e. Enterococcus hirae and 
Barnesiella intestinihominis {Daillère, 2016}), open the possibility to exploit the 
manipulation of gut microbiota to improve the efficacy of cancer therapies {McQuade, 
2019}. Intervention strategies to manipulate intestinal microbiota of cancer patients can 
range from less precise to a more specific approaches (Fig. 1.14).  
The faecal microbiota transplantation (FMT) consist in the transfer of a large 
community of bacteria and is already used for the treatment of resistant Clostridium 
difficile infectious, and it is under clinical evaluation  in cancer patients {reviewed in 
Routy, 2018b}. FMT can be performed orally or rectally by using lyophilized and 
encapsulated faeces from donor without cancer (or responsive to the treatment) to patients. 
The difficulty to find the optimal donors (including the lack of definition of favourable 
microbiota), to collect sufficient material to enable long-term and prolonged treatment, 
alongside the possibility to transfer disease-promoting bacteria such as 
obesity/carcinogenesis related bacteria, make the FMT a challenging strategy to modulate 
intestinal microbiota.  
The existing commensal community, can be shaped via prebiotics or dietary changes 
to favour the expansion of beneficial bacteria. Prebiotics are defined as “a substrate that is 
selectively utilized by host microorganisms conferring a documented health benefit” 
{Gibson, 2017}. An example of prebiotic is represented by the fructooligosaccharides 
while an unresolved question is about whether non-digestible fibre and all non-starch 
polysaccharides should be considered as prebiotics or not {Hutkins, 2016}. Nontheless, 
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this definition of prebiotics expands the concept of prebiotics to possibly include non-
carbohydrate substances such as polyphenols and polyunsaturated fatty acids, and their 
direct application to body sites other than the gut (i.e. vaginal tract and skin) {Gibson, 
2017}.  
A modification of the gut microbiota is also possible through the administration of 
probiotics, “live organisms that, when administered in adequate amounts, confer a health 
benefit on the host” {Hill, 2014}, they are generally produced by the fermentation of food 
and most of them come from two groups, Lactobacillus and Bifidobacterium, although 
many other types of bacteria are classified as probiotics (e.g. Enterococcus faecium, 
Enterococcus durans, Streptococcus thermophilus and Bacillus subtilis) {Floch, 2014}.  
The combination of prebiotics with probiotics to create “symbiotic” mixture is possible for 
an optimal expansion of favourable bacteria {Klaenhammer, 2012}.  
In theory, antibiotics could be also considered to reduce the abundance of harmful 
bacteria in the gut but they lack the precision to modulate very specific bacterial 
populations. In a more precise approach, single or defined mixture of cultivable bacterial 
species can be used as adjuvant strategy in anticancer therapies, but attention should be 
paid to create stable ecosystem of cooperating species avoiding biological resources or 
ecological niches completion among the selected bacteria {Foster, 2017}. If a bacterial 
metabolic pathway is identified together with the metabolic products favourable to 
improve antitumor immunity and immunotherapy, small molecules derived from bacteria 
can be suitable as immune-modulatory drugs (Fig. 1.14). 
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Figure 1.14 Strategies to target gut microbiota. To improve the response to treatment in 
cancer patients different strategies can be adopted to modulate the intestinal microbiota. 
For each strategies pro (blue) and cons (red) are illustrated {Helmink, 2019}. 
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The introduction of the anti-HER2 targeted therapy considerably advanced the 
treatment of women with HER2-positive BC. Despite the increment in survival benefit, a 
large number of patients progress upon the treatment even within the group of tumours 
prone to get advantage from trastuzumab treatment (HER2-enriched by PAM50 classifier 
and highly infiltrated by immune cells) rising the clinical need to understand the reason 
underlying this resistance. Moreover, existing biomarkers, such as the expression levels of 
ERBB2 and ESR1 genes, the intrinsic subtypes, and tumour immune infiltration or 
immune signatures, are able to predict the response to trastuzumab in only half of the 
patients. Suggesting the possibility of tumour extrinsic factors playing a role in the efficacy 
of anti-HER2 treatment.  
The gut microbiota has been recently investigated as a mediator of anticancer 
treatment, so far clinical and preclinical evidence showed that different intestinal 
microbiota status is associated with the efficacy of immunotherapy and certain 
chemotherapies that elicit an immune response in their mechanism of action.This evidence 
open the possibility to use the gut microbiota as both intervention strategy to improve the 
anticancer treatment efficacy or as a predictive biomarkers.  
As regard to trastuzumab, this mAbs, in addition to inhibit its target HER2, exerts a 
cytotoxic activity by recruiting the immune cells within the tumour microenvironment. 
Considering the relevance of immune cells in trastuzumab cytotoxicity and the role of 
commensal bacteria in the development and maintenance of the immune system, a possible 
role for the gut microbiota was hypothesize as a tumour extrinsic factors that contributes to 
the heterogeneity observed in trastuzumab efficacy. The ultimate goal of this project was to 
investigate the role of gut microbiota in the treatment of HER2-positive BC and the 
specific aims of my work were: 
 
57 
 
 Study the influence of commensal bacteria on trastuzumab efficacy in preclinical 
models of HER2-positive BC; 
  Investigate the possibility to exploit microorganism(s) to confer sensitivity to 
trastuzumab treatment; 
 Study the role of the gut microbiota composition in HER2-positive patients treated 
with neoadjuvant trastuzumab. 
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Chapter 3: MATERIALS AND METHODS   
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3.1 Patients cohort  
Patients with stage II-III HER2-positive breast cancer that received neoadjuvant 
trastuzumab-based therapy between 2017-2019 at the Istituti Clinici Scientifici Maugeri 
Spa–SB, Pavia, Italy, were enrolled in this study in collaboration with Dr. Fabio Corsi. 
Women received four cycles of Adriamycin/cyclophosphamide followed by four to six 
cycles of paclitaxel or docetaxel/trastuzumab (AC-TH, where A, Adriamycin; C, 
cyclophospamide; T, taxanes and H, trastuzumab). Two patients belonging to this cohort 
were treated with only TH starting from the beginning. The pCR was defined as no 
residual invasive tumour in the breast at the time of the surgery. To study the association 
between gut microbiota composition and trastuzumab treatment, faecal samples were 
collected before trastuzumab administration. To preserve the viability of anaerobic 
bacteria, faeces were collected using the ANAEROGEN
TM 
compact SYSTEM (Oxoid 
Microbiology Products, Thermo Fischer Scientific, Waltham, MA, USA). For 
metagenomics analysis, 1 g aliquots of faeces were immediately frozen at –80° C.  
For the gene expression analysis on formalin-fixed and paraffin-embedded (FFPE) 
specimens, the leftover material of samples collected during standard surgical and medical 
procedures was used. Samples were donated by the patients to the Institutional Biobank for 
research purpose, and aliquots were designated for this study after approval by the 
institutional review board and a specific request to the independent committee of the 
institutes Istituti Clinici Scientifici Maugeri (Pavia) and Fondazione IRCCS Istituto 
Nazionale dei Tumori (Milan) (Observational study n°22/16).  
Based on the relevance of the use of antibiotics in determining the gut microbiota 
content, patients were asked to report changens in the usual habits and antibiotics 
assumption. 
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3.2 Antibiotics treatment and in vivo experiments 
3.2.1 Cell lines and reagents 
The murine MI6 tumour cell line {Castagnoli, 2014} was established from 
spontaneous primary mammary carcinomas developed in a transgenic human ∆16HER2-
LUC FVB female mice (∆16HER2), a model that express the constitutively active splice 
variant ∆16 of the human HER2 proto-oncogene under the MMTV promoter {Marchini, 
2011}. MI6 cells were maintained in complete culture medium (MammoCult; Stemcell 
Tecnologies, Vancouver, Canada) supplemented with 1% foetal bovine serum (FBS; 
Sigma-Aldrich, MO, USA), penicillin 1 µg/mL and streptomycin 1 µg/mL (Sigma-
Aldrich), hydrocortisone 0.48 µg/mL (Stemcell Technologies), heparin 2 U/mL (Sigma-
Aldrich) and cultured at 37°C in a 5% CO2 atmosphere incubator. The cell line D2F2/E2 
derived from the transfection with the human HER2 gene under the CMV promoter of the 
D2F2 cell line {Piechoki, 2001}, established from a spontaneous mammary tumour that 
arose in a BALB/c. D2F2/E2 cells were cultured in DMEM (GIBCO, Thermo Fisher 
Scientific, Massachussets, USA) supplemented with 10% FBS, 1% sodium pyruvate and 
nonessential amino acids under constant selection with G418 800 µg/mL (Geneticin, 
Thermo Fisher Scientific). The TUBO cell line derived from spontaneous lobular 
mammary tumour developed in BALB/c mice transgenic for the transforming rat neu gene 
{Rovero, 2000}. TUBO were cultured in RPMI (GIBCO) supplemented with 10% FBS. 
3.2.2 Antibiotics treatment 
To study the impact of intestinal microbiota alteration on the efficacy of anti-HER2 
inhibition, vancomycin hydrochloride (vancomycin; Cayman Chemical, MI, USA) and 
streptomycin sulphate salt (streptomycin; Sigma-Aldrich) were dissolved in the drinking 
water at a concentration of 200 mg/L. For the experiments performed at the National 
Institute of Health (NIH), an antibiotic cocktail (ABX) was used to completely disrupt the 
intestinal microbiota of BALB/c mice, antibiotics were dissolved in the drinking water 
supplemented with 0.01% sweetener (sucralose Splenda ®): vancomycin 500 mg/L, 
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neomycin sulphate (neomycin; Sigma-Aldrich) 700 mg/L, Primaxin (Imipenem and 
Cilastin, Merck&Co., NJ, USA) 500 mg/L or ampicillin sodium salt (ampicillin, Sigma-
Aldrich) 1 g/L. ABX were administered to mice ad libitum starting from age four-weeks 
and changed every 48-72 h with fresh solution. 
3.2.3 In vivo experiments 
Mice were maintained in laminar-flow rooms at constant temperature and humidity, 
with food and water given ad libitum. Experimental protocols used for animal studies were 
approved by the Ethics Committee for Animal Experimentation (OPBA) of Fondazione 
IRCCS Istituto Nazionale dei Tumori of Milan and by the Italian Ministry of Health in 
accordance with institutional guidelines (projects no. 11/16 and 11/17). Experiments 
conducted at the National Istitute of Health (NIH) – National Cancer Istitute (NCI) of 
Bethesda , MD, US, were approved by the NCI-Bethesda Animal Care and Use Committee 
(protocol no. CIP-004-O/P). 
Female FVB mice or BALB/c mice (four-weeks old; body weight, 16-18 g) were 
purchased from Charles River Laboratories (Calco, Italy). Mice were administered an 
antibiotic (vancomycin or streptomycin or ABX, prepared as described in the antibiotic 
treatment paragraph) or sterile water, as control. After four weeks of antibiotic treatment,  
1×10
6
 MI6 cells were injected into the mammary fat pad of FVB mice. The anti-HER2 
mAb trastuzumab [Herceptin] (Genentech, Roche, Basel, Switzerland) was administered 
via intraperitoneal injection (i.p.) at a concentration of 5 mg/kg body weight, starting when 
tumours reached a palpable volume (~3 mm of diameter). Trastuzumab antitumor efficacy 
was evaluated as inhibition of tumour growth. Similarly, 5x10
5 
TUBO or D2F2/E2 cells 
were injected into the mammary fat pad of BALB/c mice. Animals harbouring TUBO 
tumours received 100 µg of 7.16.4 mAb (InVivo mAb, BioXcell, Lebanon, NH, USA) 
twice a week for two weeks. Mice bearing D2F2/E2 tumours were treated twice a week 
with trastzumab (5 mg/kg body weight). Untreated mice received 100 µL of NaCl solution 
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(0.9%) as control. Tumours were measured once a week, and the volume was calculated as  
0.5 × d1
2
 × d2, where d1 and d2 are the smaller and larger diameters, respectively.  
A breeding colony of ∆16HER2 mice was maintained in the Animal Facility of 
Fondazione IRCCS Istituto Nazionale dei Tumori. Ear biopsies were harvested from four-
weeks old mice for the routine genotyping. DNA was extracted using the Exgene Tissue 
DNA mini kit (GeneAll® kit , Tribioscience, California, USA) and analysed by PCR 
(primers: F ,5′-GGCTCAGTGACCTGTTTTGG-3′ and R,5′-
TGATGAGGATCCCAAAGACC-3′), with an expected amplicon length of 231 bp. 
Positive female mice were divided into two groups and one was administered vancomycin 
(200 mg/L) in the drinking water and one was kept as control. Mice were inspected weekly 
by palpation to monitor tumours onset and growth. Mice were treated with i.p. injection of 
trastuzumab at a concentration of 8 mg/kg body weight {Castagnoli, 2014} or NaCl 
solution (0.9%) starting from age 8 weeks or after tumour onset (~3 mm of diameter) 
according to the experiments. The antitumor efficacy of trastuzumab was assessed by 
evaluating tumour onset, tumour multiplicity and volume. 
3.2.4 Faecal microbiota transplantation 
The causal link between trastuzumab efficacy and gut microbiota composition was 
evaluated with a FMT experiment. The intestinal microbiota of recipient FVB mice was 
depleted by treating animals for four weeks with an antibiotic cocktail (ABX) containing 
vancomycin (500 mg/L), neomycin, ampicillin and metronidazole (Cayman Chemical) (1 
g/L) starting at four-weeks of age. Due to the reluctance of BALB/c mice to drink the 
antibiotic solution, the depletion of their gut microbiota was performed by daily oral 
gavage of 200 µL ABX solution (vancomycin 5 mg/mL, neomycin, metronidazole and 
ampicillin 10 mg/mL) for ten consecutive days {Adachi, 2017}. For the FMT, fresh faeces 
(130-150 mg) were resuspended in 1 mL of pre-reduced PBS 1X in order to preserved the 
viability of the anaerobic bacteria. Faeces were then homogenized by vortexing the sample 
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in presence of a 3 mm diameter tungsten carbide bead (QIAGEN, Hilden, Germany) and 
centrifuged at 100 rpm for 1 min to avoid big particles. Mice were transplanted using 200 
µL of faecal suspension twice a week for two weeks and then once a week until the end of 
the experiment.  
The total bacterial load and the viability of faecal samples used for the FMT were 
evaluated by flow cytometry. The concentration of cells was determined by using the 
Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA): the cell 
suspensions were double-stained with SYBR green I 1x (Sigma-Aldrich) and propidium 
iodide (PI) 0.5 µg/mL (Sigma-Aldrich), at 37°C for 15 min in the dark, in order to 
distinguish alive, injured and dead cells based on their fluorescence. The SYBR-Green I 
and the PI fluorescence of stained cells was recovered in the FL-1 channel (excitation 488 
nm, emission filter 530/30 nm) and FL-3 Channel (excitation 488 nm, emission filter 
630/30 nm), respectively. 
For the FMT experiment using faecal material from BC patients, 2 g of faeces 
collected using the ANAEROGEN
TM 
compact SYSTEM (Oxoid) were frozen after being 
homogenized in 10 mL of autoclaved brain-heart-infusion media (BHI, Sigma)  
supplemented with 0.1% L-cysteine (Sigma) and 15% glycerol. Faecal suspension was 
kept for 1 hour at room temperature inside the ANAEROGEN
TM 
compact SYSTEM bag 
(Oxoid) to remove oxygen and, then stored in 1 mL aliquots. The FMT in mice was 
performed using 200 µL of thawed faecal suspension (7-8 mice for each patient). The FMT 
was performed for a total of five times, 24-48 h before and after tumour cells injection, and 
then every ten days for additional three times. Trastuzumab treatment started when tumour 
reached a palpable volume and the mAbs was administered twice a week for 3 weeks at a 
concentration of 5 mg/kg. 
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3.2.5 Lactic acid producing bacteria treatment 
Lactococcus lactis subsp IL1403 (L. lactis) and Lactobacillus paracasei FMB (L. 
paracasei) were provided by Dr. Stefania Arioli from the Dept. of Food, Environmental 
and Nutritional Sciences (DeFENS) at the Università degli Studi of Milan. Bacteria were 
cultured anaerobically, L. lactis was grown in the M17 broth (Difco Laboratories INC., 
Detroit, MI, USA) supplemented with 1 % (w/v) glucose (Sigma-Aldrich) (gM17) at 30°C 
and L. paracasei was grown in the Man-Ragosa-Sharpe (MRS) broth (Difco) at 37° C. 
LAB suspensions to be used in in vivo treatment were prepared starting from an 
overnight culture, LAB were then washed twice with sterile saline solution (0.9% NaCl), 
and resuspended, at the concentration of  5x10
9  
cells/mL determined by using an Accuri 
C6 flow cytometer, in saline solution in presence of 10% (v/v) glycerol to preserve cells 
viability during storage at -80°C. Mice were transplanted using 200 µL of thawed 
suspension three times a week throughout the entire experiment.  
3.3 Cellular biology 
3.3.1 Immunofluorescence analyses 
Immunofluorescence (IF) analyses were performed to detect trastuzumab distribution 
within the tumours. Tumour samples were embedded in the O.C.T. compound 
(AgarScientific Ltd, Stansted, UK) and stored at -80°C. Tissue specimens were cut on the 
cryostat microtome and sections were fixed with 4% paraformaldehyde for 20 min at room 
temperature. Tumours sections were then incubated with a blocking solution with 3% BSA 
before being stained with the anti-human AlexaFlour®568 secondary antibody at a dilution 
of 1:100 for 1 hour at room temperature. Nuclei were counterstained with DAPI (Thermo 
Fischer Scientific). Images were acquired at the microscopy facility of Fondazione IRCCS 
Istituto Nazionale dei Tumori using a confocal laser scanning microscope Leica TCS SP8 
X (Leica Microsystems GmbH, Mannheim, Germany). The fluorochrome was excited by a 
pulsed super continuum White Light Laser (470-670nm; 1nm tuning step size). In 
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particular, AlexaFluor-568 was excited selecting 557 nm laser line and detected from 562 
to 642 nm; and DAPI excited with 405 nm diode laser and detected from 422 nm to 488 
nm. Four images were acquired for each sample in the scan format 512x512 using HC PL 
APO 40X/1.3 CS2 oil immersion objective and a pinhole set to 1 Airy unit. Data were 
analysed using the public available ImageJ software for image processing. 
3.3.2 Immunohistochemistry analyses 
The expression of HER2 was evaluated by immunohistochemistry (IHC) on FFPE 
tumour tissue from no antibiotic and vancomycin or streptomycin treated mice collected at 
the end of the experiment. Tumour slides were deparaffinised and serially rehydrated, the 
antigen retrieval was performed using 10 mM citrate buffer, pH 6 at 96°C for 6 min. Slides 
were then stained with the rabbit anti-p185 (clone A0485 - Dako, Agilent Technologies, 
Santa Clara, CA, USA) at 1:150 dilution. Immunoreactions were visualised using 
streptavidin-biotin-peroxidase (Thermo Fisher Scientific) and the 3,3’ Diaminobenzidine 
(DAB) Chromogen System followed by counterstaining with haematoxylin. Quantification 
was performed using the public available ImageJ software for image processing. 
The characterization of the tumour immune infiltrate was carry out by Dr. Tripodo at 
the Dept. of Human Pathology of the Università degli Studi of Palermo. For the IHC 
analyses four-micrometre-thick FFPE tissue section were deparaffinised and rehydrated. 
The antigen unmasking was performed using Novocastra Epitope Retrieval Solutions  pH 9 
(Novocastra, Newcastle Upon Tyne, UK) in a PT Link pre-treatment module (Dako, 
Denmark) at 98°C for 30 min. The sections were brought to room temperature and washed 
by a specific protein block (Novocastra) the slides were incubated over night with the 
primary antibodies at 4 C°. Table 3.1 lists all the molecules evaluated and the antibodies 
used for the staining. The staining was revealed by AEC (3-amino-9-ethylcarbazole) 
substrate-chromogen following producer’s instruction. The slides were counterstained with 
Harris haematoxylin (Novocastra). All the sections were analysed under an AXIO Scope 
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A1 optical microscope (ZEISS, Oberkochen, Germany) and 5 sections were counted at 40x 
magnification microphotographs were collected through an Axiocam 503 Colour digital 
camera (Zeiss) using the Zen2 software. 
Table 3.1 List of antibodies used for IHC analyses 
Molecule Host Clone Dilution Brand 
CD45 Rabbit ab10558 1:1000 Abcam 
CD3 Rabbit ab5690 1:100 Abcam 
CD4 Rat 4SM95 1:100 eBIOSCIENCE 
CD8 Rat 4SM15 1:100 eBIOSCIENCE 
GranzymeB Rabbit 760-4283 Ready to use Venatana 
ArginaseI Rabbit GTX109242 1:200 Genetex 
CD31 Mouse 1A10 1:50 Leica Novocastra 
Gr-1 Rat RB6-8C5 1:100 BioLegend 
3.3.3 Flow cytometry analyses 
Tumours were harvested at the end of the experiment for the immune phenotype 
analysis. Samples were cut into small pieces and digested in DMEM medium containing 
Collagenase IV (100 µg/mL) and DNAse I (200 U/mL) for 50 min at 37°C under constant 
agitation. The tumour suspension was filtered through a cell strainer with 40 µm pore 
diameter. The red blood cells lysis was performed by incubating tumour cells suspension 
with ACK (Sigma) on ice for 5 min. Tumour pellet was then resuspended in 1 mL of 
FACS buffer (PBS 1x, 2% FBS and 2mM EDTA), 200µL of cells suspensions were 
stained with primary antibody directly conjugate with fluorophores (Table 3.2 and 3.3) for 
15 min at 4°C. Dead cells were excluded using the LIVE/DEAD Fixable Blue (or Near-IR) 
Dead Cell Stain Kit (Thermo Fisher Scientific). Stained samples were fixed 15 min at 4°C 
with 1% formalin and run on a BD LRS Fortessa SORP II (BD Bioscience) cytometer at 
the flow cytometry facility of the National Institute of Health (NIH) (Bethesda, MD, USA) 
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or on a BD FACSCanto system (BD Bioscience) at the flow cytometry facility of the 
Fondazione IRCCS Istituto Nazionale dei Tumori. The analysis was then performed using 
the FlowJo software (Tree Star, Ashland, OR, CA, USA). 
Table 3.2 Antibodies for flow cytometry BD LRS Fortessa SORP II  
Molecule Conjugate Clone Dilution Brand 
CD45 BUV737 104 1:100 BD Biosciences 
CD45 eFluor450 30-F11 1:100 eBioscience 
CD3 PerCPCy5.5 17A2 1:200 Biolegend 
CD4 BUV395 GK1.5 1:100 BD Biosciences 
CD8 APC Cy7 53-6.7 1:100 BD Biosciences 
TCRβ  APC H57-597 1:200 BD Biosciences 
CD19 BV650 1D3 1:200 BD Biosciences 
CD49b PE DX5 1:200 Biolegend 
CD44 BUV737 IM7 1:100 BD Biosciences 
CD62L BV786 MEL-14 1:200 BD Biosciences 
MHCII BV605 2G9 1:1000 BD Biosciences 
TCRγδ  FITC GL3 1:100 BD Biosciences 
CD24 BV650 M1/69 1:100 BD Biosciences 
Ly6G PECy5 1A8 1:200 BD Biosciences 
Ly6G BUV395 1A8 1:100 BD Biosciences 
Ly6C Alexa Fluor647 HK1.4 1:1000 Biolegend 
CD86 BV786 GL1 1:200 BD Biosciences 
F4/80 BV711 T45-2342 1:300 BD Biosciences 
F4/80 PECy5 BM8 1:200 BD Biosciences 
CD11c PerCp Cy5.5 N418 1:200 Biolegend 
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CD11b PE-CF594 M1/70 1:500 BD Biosciences 
CD206 PECy7 MMR 1:200 Biolegend 
CD64 PE X54-5/7.1 1:200 BD Biosciences 
 
Table 3.3 Antibodies for flow cytometry BD FACSCanto 
Molecule Conjugate Clone Dilution Brand 
CD3 FITC 145-2C 1:10 MACS 
CD49b PE DX5 1:100 MACS 
CD4 PEVio770 GK.15 1:10 MACS 
CD8 PECy5 53.6.7 1:100 eBioscience 
CD19 APC 6D5 1:10 MACS 
CD11b PE ICRF44 1:100 BD pharmingen 
CD11c PECy7 N418 1:100 BD pharmingen 
F4/80 PerCPCy5.5 BM8 1:100 eBioscience 
Ly6C APC 1G7.G10 1:10 MACS 
Ly6G FITC 1A8 1:10 MACS 
 
3.4 Metagenomic analyses and molecular biology  
For murine studies, faeces were collected from 10 mice per group of treatment 
before the beginning of trastuzumab administration or at the end of the experiment and 
were conserved at -80°C. The metagenomic DNA was extracted from one stool pellet. For 
the analysis of gut microbiota in patients, the DNA was extracted from 200 mg of faeces 
conserved at -80°C.  
In the analysis of faecal microbiota sample, several aspects should be taken into 
consideration as possible sources of variation. Faecal sample preparation and storage can 
introduce bias during downstream analyses affecting the 16S rRNA gene sequencing. Our 
study was conducted on faecal samples conserved at –80°C for short/long period (<2 
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years) according to the experiment. Although freezing sample has been shown to cause an 
increment in the relative abundance of Bacteroidetes and Firmicutes as compared to 
freshly analysed samples {Bahl, 2016}, the most critical factor that influences the results 
on bacteria composition remains the method used for the DNA extraction {Videnska, 
2019}. In addition, samples stored for long term (>2 years) at -80°C have demonstrated 
enough stability to be considered still largely representative of the original community 
{Shaw, 2016; Tap, 2019}. For these reasons, we do not expect relevant biases derived 
from storage conditions or extraction methods in our analyses of 16S rRNA gene profile. 
In fact, the same DNA extraction kit was used, and all samples were stored at –80°C for a 
period of time lower than 2 years thus inter-individual variation should be much greater 
than that attributable to storage conditions.   
3.4.1 Microbial DNA extraction  
The metagenomic DNA was extracted by using the DNeasy PowerLyzer PowerSoil 
DNA isolation kit (QIAGEN, Hilden Germania) according to the following adapted 
protocol: samples were transferred to the PowerLyzer glass bead tubes and 750 µL of Bead 
solution were added and the samples vortexed. Then 60 µL of Solution  C1 were added, 
vortexed and heated 10 min at 65° C. Feaces were homogenized using the Tissuelyzer II 
machine (QIAGEN) for 5 min with oscillation frequency of 30/sec. Samples were then 
centrifuged at 10000 rpm for 10 min at room temperature. Solution C2 and C3 were added 
simultaneously and incubated at 4° C for 5 min. Samples were then centrifuged and 1200 
µL of Solution C4 were added to the supernatant and vortexed. Samples were passed 
through the Spin Filters by centrifugation at 10000 rpm. Solution C5 (500 µL) was added 
to wash the filters and DNA was eluted in 50 µL of DNAse and RNAse - free H2O. The 
DNA extracted from faecal samples was quantified using a Qubit 2.0 fluorimeter 
(Invitrogen, Thermo Fisher Scientific). 
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3.4.2 16S rRNA gene sequencing and analyses 
To analyse the composition of the bacterial community the 16S rRNA gene was 
profiled. The DNA extracted was normalized to a final concentration of 5 ng/µL and a 
fragment encompassing the variable regions 3 and 4 (V3 and V4) of the 16S rRNA gene 
was amplified from 12.5 ng of total DNA and sequenced on the MiSeq Illumina 
Technology (Illumina, Inc, San Diego, CA, USA) platform at the Centre for Life 
Nanosciences, Italian Insitute of Technology (Rome, Italy). The raw data of the DNA 
sequencing were analysed in collaboration with Dr. Simone Guglielmetti and Dr. Giorgio 
Gargari at the DeFENS (Università degli Studi of Milan), using the open-source 
bioinformatics Quantitative Insights Into Microbial Ecology (QIIME) version 1.9.1 
{Caporaso, 2010}. Bacterial abundances in each faecal sample were reported at the 
taxonomic level of genus. The ecological diversity (alpha and beta) were calculated by 
QIIME software version 1.9.1. The α-diversity of microbial composition was analysed 
using three different indexes Chao1, Shannon and Simpson indexes: Chao1 index weighs 
the richness of different bacteria present in each sample; Shannon and Simpson indexes are 
mainly influenced by the evenness plus richness and to the evenness respectively.  
Principal component analyses (PCoA) were done based on UniFrac distance matrices 
{Lozupone, 2005} to visually compare the microbiota of the different treatment groups 
considering bacterial phylogenetic distances. In the analysis of patient’s β-diversity, the 
unsupervised clustering by JSD algorithm was performed: the Calinski-Harabasz index 
(CH) together with Silhouette method of interpretation and validation of consistency 
within clusters data was applied to figure out the best clustering possible represented with 
the ellipse in the β-diversity.  
Linear discriminant analysis (LDA) effect size analysis (LEfSe) was performed to 
identify differentially abundant taxa {Segata, 2011} in groups of treatment of R and NR 
patients. Specifically, the algorithm uses the non-parametric factorial Kruskal-Wallis sum-
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rank test associated with a p-value correction test to detect features with significant 
differential abundance with respect to the group of interest. Statistical significance was set 
at p ≤ 0.05, and mean differences with 0.05 < p ≤ 0.10 were accepted as trends. 
3.4.3 RNA extraction and qRT-PCR 
To evaluate the expression of intratumor cytokines, RNA was extracted from frozen 
tumours. Samples were transferred in vials containing 1 mL of QIAzol Lysis Reagent 
(QIANGEN) and homogenized with the TissueLyser system (QIAGEN)  with the help of a 
3 mm tungsten carbide bead (QIAGEN) inside the vials. Samples were centrifuged at 1500 
rpm at 4°C and the supernatant transferred to new vials. RNA was extracted according to 
manufacturer’s instructions. The cDNAs were reverse transcribed  from 2 µg of total RNA 
by using the High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific), the gene 
expression level was assessed by qRT-PCR using the TaqMan probe-based assays and the 
TaqMan Fast Universal PCR Master Mix (Applied Biosystem, Thermo Fisher Scientific) 
on the ABI Prism 7900HT sequence detection system (Applied Biosystem, Thermo Fisher 
Scientific). The total 16S rRNA in faecal samples was quantified by using the SYBR 
Green PCR Master Mix (Applied Biosystem, Thermo Fisher Scientific). Table 3.4 lists the 
TaqMan Gene Expression Assays and probes that were used.  
Table 3.4 List of Taqman assays and probes used for qRT-PCR analysis 
Gene Taqman assay Code 
Ifng Mm01168134_m1 
Il12a Mm00434169_m1 
Il15 Mm00434210_m1 
Il6 Mm00446190_m1 
Il10 Mm01288366_m1 
Tgfb1 Mm01178820_m1 
Gapdh Mm99999915_g1 
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Probe  Sequence 
U16S-Forward 5’-ACTCCTACGGGAGGCAGCAGT-3’ 
U16S-Reverse 5’-ATTACCGCGGCTGCTGGC-3’ 
 
 3.4.4 Gene expression profile 
GEP on patients tumour biopsies were performed in collaboration with the 
Functional Genomic and Bioinformatic Facility of our Institute. RNA was extracted from 
FFPE samples using miRNAeasy FFPE kit (QIAGEN). After quality check and 
quantification by 4200 TapeStation (Agilent Technology) and Qubit Fluorometer (Thermo 
Fisher Scientific), respectively, RNA expression was assessed using the human Affymetrix 
Clariom S Pico assay (Thermo Fisher Scientific). The single-stranded cDNA samples for 
hybridization was generated by 100 ng of total RNA. Then, cDNA was enzymatically 
fragmented and biotinylated using the WT Terminal Labeling kit (Thermo Fisher 
Scientific), combined with the hybridization buffer, and injected into the Human Clariom S 
arrays targeting >20,000 well-annotated genes. Arrays were stained using the Affymetrix® 
GeneChip® Fluidics Station 450 and scanned with the 7G Affymetrix® GeneChip® 
Scanner 3000. Raw data were processed using Transcriptome Analysis Console software 
(Thermo Fisher Scientific). CEL files containing feature intensity values were converted 
into summarized expression values by Robust Multi-array Average (RMA) which consists 
of background adjustment, quantile normalization across all chips. All samples passed QC 
thresholds for hybridization, labelling and the expression of housekeeping gene controls. 
The data will be deposited into the Gene Expression Omnibus repository. The research-
based PAM50 subtypes predictor was applied using the publicly available algorithm as 
described after merging of the dataset with 50 consecutive BC cases profiled on the same 
platform in our Institute, performing median centring of the PAM50 genes {Prat, 2014a}.  
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3.5 Microbial metabolic analyses 
Short-chain fatty acid (SCFAs) and lactate were measured in faecal and plasma 
sample. The quantification of faecal SCFAs in mice under vancomycin and streptomycin 
treatment, was performed in collaboration with Dr. Claudio Gardana at the Università degli 
Studi of Milan. Approximately 100 mg of faecal sample was suspended in 2 mL of a 
solution 0.001% HCOOH in water containing 2-MBA (IS, 50 μmolar). After vortexing for 
1 min, the suspension was centrifuged at 10,000 x g for 1 min, and the supernatant was 
collected into a 5 mL flask. The residue was treated with 2 mL of a solution 0.001% 
HCOOH in water containing 2-MBA (50 μmolar), vortexed for 1 min and centrifuged at 
10,000 x g for 1 min. The supernatant was pooled; the volume was adjusted to 5 mL with 
0.001% HCOOH in water containing 2-MBA (50 μmolar) and the solution stored at 
−20 °C until analysis. Determination of SCFAs concentration was achieved through 
ultraperfomance liquid chromatography-high resolution-mass spectrometry analysis 
(UPLC-HR-MS). UPLC-HR-MS analysis was carried out on an Acquity UPLC separation 
module (Waters, Milford, MA, USA) coupled with an Exactive Orbitrap MS with an 
HESI-II probe for electrospray ionization (Thermo Fisher Scientific) {Gargari, 2016}. 
The analysis of SCFAs from murine plasma samples and faecal sample of HER2-
positive BC patients were performed by the company ProDigest (Gent, Belgium).  
Lactate quantification was performed using commercially available enzymatic assay 
kit (Lactate Assay kit, r-biopharm, Boehringer Mannheim, Germany). 
3.6 Statistical analyses 
Analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc, CA, 
USA). Differences between groups were determined using the two-tailed unpaired t test. 
Differences among α-diversity in microbial samples were determined by the Mann-
Whitney-Wilcoxon test. Statistical significance was set at p<0.05, and mean differences 
with 0.05 < p ≤ 0.10 were accepted as trends.   
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4.1 Impact of gut microbiota on trastuzumab efficacy in the FVB murine model  
4.1.1 Trastuzumab efficacy in antibiotic-treated FVB mice 
The role of commensal bacteria in the therapeutic benefit of anti-HER2 treatment, 
was investigated in antibiotic-treated FVB mice, that harboured MI6 cell tumours, a 
HER2-positive cell lines established from spontaneous mammary tumours developed in 
Δ16HER2 FVB female mice {Castagnoli, 2014}. Vancomycin and streptomycin were used 
in this study based on their poor intestinal absorption {Rao, 2011; Krause, 2016}. 
Vancomycin is mainly directed against Gram-positive bacteria acting as inhibitor of the 
peptidoglycan biosynthesis {Hammes, 1974}, while streptomycin is a broad spectrum 
antibiotics that inhibits the proteins synthesis in bacteria causing cell death {Luzzato, 
1968}. The administration of antibiotic in mice started at age four-weeks and continued for 
the entire duration of the experiment, and MI6 cells were injected into the mammary fat 
pad of mice after four weeks of treatment. The therapy with trastuzumab started when 
tumours reached a palpable volume, and its efficacy was evaluated measuring tumour 
growth inhibition (Fig. 4.1). Antibiotic abrogated trastuzumab efficacy as compared to 
control (no antibiotic, NoA) animals. 
Figure 4.1 Efficacy of trastuzumab in antibiotic-treated mice. A-C) Tumour growth 
measurement in control mice (NoA) (A), vancomycin (B), or streptomycin (C) (200 mg/L) 
treated mice. Trastuzumab was administered i.p. at a concentration of 5mg/kg body weight 
twice a week starting when tumours reached a palpable volume. (Black, tumor growth in 
untreated mice; red, tumour growth in mice treated with trastuzumab). * p<0.05 and **p< 
0.01 by unpaired Student’s t-test.  
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To assess whether antibiotics have an impact on tumours and could possibly impair 
the binding of trastuzumab to its target, HER2 expression, tumour vasculature and the 
mAb distribution within the tumour were evaluated (Fig. 4.2 and 4.3). IHC analyses 
carried out of FFPE tumour specimens (Fig. 4.2 A), did not reveal differences in HER2 
expression among the three groups of treatment (Fig. 4.2 B). Furthermore, since 
abnormalities in the tumour vasculature can have negative consequences on the 
homogeneous drugs distribution within the tumour {Klein, 2019} and certain classes of 
antibiotic are reported to have anti-angiogenic properties {Miyake, 2019}, we evaluated 
whether vancomycin and streptomycin had an impact on tumour vessels by staining 
specimens for CD31, a transmembrane glycoprotein expressed on endothelial cells (Fig. 
4.2 A ). The count of CD31+ cells, showed that the oral treatment with vancomycin and 
streptomycin did not alter the number of tumour vessels (Fig. 4.2 B).  
 
Figure 4.2 Characterization of tumour microenvironment in antibiotic-treated mice. 
A) Evaluation of  HER2 expression and CD31+ cells by IHC. B) Quantification of HER2 
by using the ImageJ software, and count of CD31-positive cells.  
 
Furthermore, IF analysis on OCT-frozen tumours samples revealed no differences in 
trastuzumab distribution within the tumours of vancomycin-treated mice as compared to 
controls (Fig. 4.3 A-B). 
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Figure 4.3 Trastuzumab distribution in tumours. A) Representative images of 
trastuzumab distribution in tumours from control (NoA) and vancomycin treated-mice as 
evaluated by IF using an antibody specific for the human IgG1. Blue: dapi, red: 
trastuzumab. B) Quantification of red pixels by using Image J software on 4 images per 
group (data shown as mean±SD). 
 
Altogether these data ruled out a possible antibiotic-induced tumour changes that led 
to the inefficient interaction between trastuzumab and its target.   
4.1.2 Analysis of antibiotic-induced alterations of the intestinal microbiota 
4.1.2.1 Metagenomic analysis of gut microbiota composition 
The structure of the intestinal bacterial community was evaluated in mice under 
vancomycin or streptomycin treatment. Stool samples were collected before the beginning 
of the treatment with trastuzumab and the gut microbiota composition was analysed by 
sequencing the 16S rRNA gene on the Illumina MiSeq platform. The treatment with 
antibiotic significantly reduced taxonomic richness, as reflected by the lower α-diversity 
indexes Chao1, Shannon and Simpson (Fig. 4.4 A) in vancomycin and streptomycin-
treated animals compared to controls. Vancomycin had the strongest impact on α- and β-
diversity, although also streptomycin induced relevant changes in the gut microbial 
composition as shown by the PCoA of the β-diversity (Fig. 4.4 B and C).  
A detailed phylogenetic analysis revealed that bacterial taxa belonging to the 
Actinobacteria and Firmicutes phyla decreased upon antibiotic administration. In addition, 
vancomycin treatment induced a substantial loss of members from the taxonomic phyla 
Bacteroidetes, while the relative abundance of phyla such as Proteobacteria and 
Verrucomicrobia was found to be increased. Inside the phylum Firmicutes, both antibiotics 
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determined the reduction of numerous taxa belonging to the order of Clostridiales, and 
particularly to the family Lachnospiraceae. (Fig. 4.4 D).  
 
Figure 4.4 Antibiotic-induced changes in the intestinal microbiota. Analysis of gut 
microbiota composition by sequencing the 16S rRNA gene in faeces from control (NoA), 
vancomycin or streptomycin-treated mice. A) Microbial α-diversity between control and 
vancomycin or streptomycin-treated mice calculated by Chao1, Shannon and Simpson 
indexes, **p<0.01 and ***p< 0.001 by Mann-Whitney-Wilcoxon test. B-C) Principal 
coordinate analysis plot of microbial β-diversity between control (white) group and 
vancomycin (B, blue) or streptomycin (C, green) treated animals generated using 
unweighted UniFrac algorithm. D) Heatmap of bacterial taxa relative abundance in the 
three groups of treatment. Green (low)-red (high)  relative abundance, white, not detected. 
 
To further explore these findings, a high-dimensional class comparison using linear 
discriminant analysis effect size (LEfSe) was performed in order to identify differences in 
the bacteria abundance among the three groups (Fig. 4.5 A and B). Firmicutes taxonomic 
phylum, in particular families from the Clostridiales taxonomic order (e.g. 
Ruminococcaceae and Lachnospiraceae), Bacteroidales (e.g Rikenellaceae and 
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Prevotellaceae) were represented only in control animals (red) while the guts of 
vancomycin (blue) and streptomycin (green) treated mice were mainly colonized by 
members of  Proteobacteria plus Verrucomicrobia, and Bacteroidetes, respectively. 
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Figure 4.5 Compositional differences in the gut microbiota of antibiotic-treated mice. 
Differences in the gut microbiota of vancomycin or streptomycin treated FVB mice were 
analysed by high-dimensional class comparison using linear discriminant analysis effect 
size (LEfSe). The significant differences among group of treatment were highlighted. 
Control (NoA, red), streptomycin (green) and vancomycin (blue). A) Linear discriminant 
analysis (LDA) scores computed for differentially abundant taxa in the faecal 
microbiomes, length indicates effect size associated with a taxa. B) Taxonomic cladogram 
from LEfSe showing differences in faecal bacteria, the background colour indicates which 
bacterial order is differentially abundant in each group of treatment. Dot size is 
proportional to the bacteria abundance.  
 
 
4.1.2.2 Quantification of bacterial metabolites in faecal and blood samples 
Based on the key role of bacterial metabolites and SCFAs in the communication 
between gut microorganisms and host, the impact of vancomycin and streptomycin on 
SCFAs production was analysed in faeces and blood samples of treated mice. Consistently 
with the strong modification of the intestinal microbiota composition, the levels of 
butyrate, propionate, and acetate were markedly decrease in vancomycin-treated animals 
(Fig. 4.6 A), while a high variability was observed in samples from streptomycin group. 
Furthermore, in the attempt to link the modification occurred in the gut to the systemic 
impact of intestinal microbiota modification, butyrate, propionate, and acetate were 
quantified in the plasma of antibiotic treated mice (Fig. 4.6 B). The analysis revealed a 
decrease in the amount of circulating SCFAs in animals under antibiotic treatment, 
however, the interpretation of these results is limited by the low amount of material used 
for the analysis (200 µL) that gave result values considered below the limit of 
quantification (LOQ).  
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Figure 4.6 Short chain fatty acids quantification in antibiotic-treated mice. Products of 
bacteria metabolism were analysed in faecal (A) and plasma (B) samples. The analysis was 
performed by ultraperfomance liquid chromatography- high-resolution-mass spectrometry 
analysis (UPLC-HR-MS). Results obtained for plasma samples were  <LOQ .** p<0.01; 
*** p<0.001 by unpaired Student’s t-test. 
 
Together with SCFAs, the amount of lactic acid was quantified in faeces of antibiotic 
treated mice. In our model antibiotic-induced modification of intestinal microbiota resulted 
in a strong decrease in the levels of total lactate (Fig. 4.7). 
 
 
Figure 4.7 Lactic acid quantification in antibiotic-
treated mice. Lactate was analysed in faecal sample 
from vancomycin or streptomycin-treated mice by 
using the lactate-quantification kit. * p<0.05; *** 
p<0.001 by unpaired Student’s t-test. 
  
 
 
 
The data obtained demonstrated alterations in intestinal metabolites following 
antibiotic treatment and, even though these results should be considered with caution, they 
indicate that perturbation of the intestinal microbiota had systemic consequences that may 
explain how gut microbiota modification impact the efficacy of the anti-HER2 treatment in 
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a distant tumour site. Furthermore, changes occurred in the levels of lactic acid let us 
hypothesise the possibility to improve trastuzumab efficacy by using lactate producing 
bacteria (as shown in section 4.1.6). 
4.1.3 Characterization of the tumour immune microenvironment in FVB mice 
4.1.3.1 Immunohistochemistry analysis of the tumour immune infiltrate  
Tumours of antibiotic-treated mice were characterized by IHC for immune cell 
infiltration. Since the efficacy of trastuzumab has been described to be mediated by cells of 
the innate and adaptive immunity, tumours were stained for CD45, CD3, CD4, CD8 
granzyme B (GZMB), Gr-1 (granulocytic marker) and Arginase I (M2-like maker) in 
collaboration with Dr. Tripodo at the Dept. of Human Pathology of the Università degli 
Studi of Palermo. The count of stained cells was reported as a total number or as a count of 
intratumor or stromal cells (Fig. 4.8). 
Figure 4.8 Immune cells localization within the tumour analysed by IHC. 
Representative IHC staining of intratumor and stromal CD45+ immune infiltrate. Original 
magnification 40x. Scale bar 50 µm. 
 
The staining showed a common increment in the total number of CD45+ immune 
cells in tumours of antibiotic-treated mice (Fig. 4.9 A). The administration of vancomycin 
and streptomycin was associated with a lower number of tumour infiltrating CD3+ 
lymphocytes (Fig. 4.9 B) while the myeloid tumour infiltrate as analysed by the Gr-1 
staining, was found to be increased (Fig. 4.9 C).  
 
INTRATUMORAL STROMAL
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Figure 4.9 Analysis of tumour immune infiltrate in antibiotic treated mice. Tumour 
samples were characterized by IHC for the immune cell infiltrates. A-C) Count of total 
CD45+ (A), CD3+ cells (B), Gr-1+ cells (C). D-E) Intratumor and stromal staining of 
CD4+ T cells (D), and granzyme B (GZMB) positive (E). Control (NoA), vancomycin (V) 
or streptomycin (S) treated mice treated or not with trastuzumab. Intratumor (white) and 
stromal (grey). (Data are shown as box and whiskers plot, min to max) * p<0.05; ** 
p<0.01 and *** p<0.001 by unpaired Student’s t-test. 
 
Interestingly, trastuzumab increased the number of intratumoral CD4+ T cells 
associated with their concomitant decrease in the stromal compartment (Fig. 4.9 D). The 
redistribution of CD4+ cells in the tumour microenvironment was observed only in the 
group of control animals but not in mice under vancomycin or streptomycin regimen. 
Similarly, the number of GZMB+ cells increased upon the anti-HER2 treatment in the 
tumours of control mice, but not in those under antibiotic regimens (Fig. 4.9 E). The IHC 
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staining also revealed a low number of CD8+ T cells that infiltrate MI6 tumours, and 
mostly localized in tumour stroma (Fig. 4.9 F) and differently from the other immune 
subset no intratumoral increment of the CD8+ T cells number was observed upon 
trastuzumab administration even in control mice. Arginase I is usually analysed as marker 
of M2-like macrophages but can also be expressed by neutrophils, the basal number of 
Arg1+ cells was increased in tumours from streptomycin treated mice as compared to 
tumours of control mice, suggesting the establishment of an immunosuppressive 
microenvironment. We also observed the increment of Arg1+ cell upon trastuzumab in 
control mice, this may reflect an accumulation of macrophages/neutrophils in the tumour 
microenvironment after several treatments with the mAb, as the tumours were collected at 
the end of the experiment. 
4.1.3.2 Analysis of intratumor cytokines expression  
The expression of pro- and anti-inflammatory cytokines was analysed by quantitative 
PCR in tumours to add information to the immune characterization performed by IHC.  
Trastuzumab treatment promoted the expression of proinflammatory cytokines in control 
animals: (Fig. 4.10): a trend towards the increment of Ifng (p=0.08) and a concomitant 
increase of Il12a and Il15 expression were found. IL12a and IL15 are two cytokines 
relevant for trastuzumab activity and they are released by macrophages and mononuclear 
cells, respectively, to induce proliferation and activation of NK cells and Th1 lymphocytes. 
Furthermore, no modulation of Il12a and Il15 was seen upon trastuzumab treatment in 
antibiotic-treated mice despite their higher basal expression levels as compared to tumours 
of control animals (Fig. 4.10 A-C). No modulation of Il6 and Il10 can be appreciated in 
this analysis while tumours of vancomycin-treated mice presented higher expression of 
Tgfb than controls (Fig. 4.10 D-F). 
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Figure 4.10 Evaluation of intratumoral cytokines expression. RNA was extracted from 
frozen tumours and the expression of Ifng (A) , Il12a (B), Il15(C), Il6 (D), Il10 (E), and 
Tgfb1 (F) was analysed by qRT-PCR. * p<0.05 by unpaired Student’s t-test. 
 
Overall, the characterization of tumour immune microenvironment revealed an 
association between changes in the gut microbiota composition and tumour immune 
infiltrate. Further analysis focused on immune cells activation and ad hoc experiment 
should be performed in future to address the mechanism underlying the influence of 
commensal bacteria on tumour immune microenvironment.  
4.1.4 Causal role of the gut microbiota in trastuzumab efficacy 
4.1.4.1 Faecal microbiota transplantation  
To explore the cause-effect relationship between gut microbiota composition and 
trastuzumab anti-tumour activity, a FMT experiment was performed. The intestinal 
microbiota of FVB mice was depleted with a cocktail of broad-spectrum antibiotics (ABX) 
(vancomycin 500 mg/L, neomycin, ampicillin and metronidazole 1 g/L) before being 
transplanted with faecal suspension from donor antibiotic-treated or control mice. The 
efficiency of  intestinal microbiota depletion was assessed after four weeks of ABX 
treatment by flow cytometry and analysis of the 16S rRNA gene (Fig. 4.11). Faeces were 
homogenized and stained for the quantification by flow cytometry: an average of 2x10
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event/mL versus 3.4x10
6
 event/mL were observed respectively in control versus ABX 
faecal suspensions (Fig. 4.11 A). In parallel, the quantification of the total 16S rRNA gene 
by qRT-PCR confirmed a significant decrease in the total bacterial load in ABX-treated 
mice (Fig. 4.11 B). The efficiency of FMT was assessed by flow cytometry by analysing 
the viability of bacteria contained in faecal suspension and faeces collected from recipient 
mice, before and 24h after the faecal transplant (Fig. 4.11 C). As shown in figure, bacteria 
harvested from donor mice maintained viability and were efficiently transferred to 
recipient animals.  
Figure 4.11 Quantification of total bacterial load in ABX-treated mice. A cocktail of 
broad-spectrum antibiotics (ABX) (metronidazole, ampicillin, neomycin 1 g/L, 
vancomycin 0.5 g/L) was administered in the drinking water of four-weeks old FVB 
female mice for a period of 28 days to deplete their intestinal microbiota. A) Equal amount 
of faeces from control (NoA) and ABX-treated mice were homogenized in pre-reduced 
PBS (130 mg/mL) and it was stained with propidium iodide (PI) and SYBR green and 
quantified by flow cytometry. The average count of three replicates is shown B) Bacterial 
load quantification by qRT-PCR using universal primers for 16S rRNA gene. **p< 0.01 by 
unpaired Student’s t-test. C) Representative images of donor stool suspensions and faecal 
samples from recipient mice as analysed by flow cytometry before and after FMT to assess 
bacteria viability and transplant efficiency. Red: transferred bacteria population. 
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 The therapeutic efficacy of trastuzumab was then assessed in FMT-mice bearing 
MI6 tumours and we observed that the inhibition of tumour growth upon anti-HER2 
treatment was more effective in mice transplanted with faeces from control animals (FMT-
NoA) than in FMT-vancomycin mice (Fig. 4.12 A-B) while in FMT-streptomycin mice 
only an initial unresponsiveness to the treatment was observed (Fig. 4.12 C). 
 
Figure 4.12 Trastuzumab efficacy in gut microbiota transplanted mice. The intestinal 
microbiota of four-weeks old FVB mice was depleted by using ABX administered in the 
drinking water (vancomycin 0.5 g/L, metronidazole, ampicillin and neomycin 1 g/L) for 
four weeks. Then, MI6 cells were injected into the mammary fat pad of ABX-treated mice 
and their microbiota was reconstituted via FMT using faecal suspension from donor mice 
treated or not with vancomycin or streptomycin. FMT was performed twice a week for two 
weeks and then once a week for the entire duration of the experiment. Trastuzumab was 
administered biweekly (at a concentration of 5 mg/kg body weight) starting when tumour 
reached a palpable volume. Untreated (black) and trastuzumab (red). * p<0.05; ** p<0.01; 
*** p<0.001 by unpaired Student’s t-test. 
 
4.1.4.2 Analysis of β-diversity in FMT-mice 
The intestinal ecology of FMT-mice was evaluated by sequencing the 16S rRNA 
gene in faeces collected at the end of the experiment for each group of treatment. The 
analysis of β-diversity was performed based on UniFrac distant matrix and the PCoA plot 
showed that, samples from FMT-vancomycin mice segregated more distant from control 
mice than samples from FMT-streptomycin mice (Fig. 4.13). Suggesting that the robust 
modifications of intestinal microbiota induced by vancomycin were better recapitulated in 
FMT-mice (Fig. 4.13 A) and maintained until the end of the experiment than in FMT-
streptomycin mice (Fig. 4.13 B). The similarity between FMT-NoA and FMT-
FMT no antibiotic
0 10 20 30
0
200
400
600
800
1000
**
**
*
**
***
days after treatment
T
u
m
o
r 
v
o
lu
m
e
, 
m
m
3
FMT vancomycin
0 10 20 30
0
200
400
600
800
1000
days after treatment
FMT streptomycin
0 10 20 30
0
200
400
600
800
1000
Untreated
Trastuzumab
*
*
*
days after treatment
A CB
88 
 
streptomycin can possibly explain why FMT-streptomycin mice responded to trastuzumab 
at the end of the experiment. 
 
Figure 4.13 Analysis of β-diversity in donor mice and FMT mice. Principal coordinate 
analysis plot of microbial β-diversity between FMT-NoA group and FMT-vancomycin (A, 
blue) or FMT-streptomycin animals (B, green) generated using unweighted UniFrac 
distance matrices. Represented are data from FMT mice (O) and donor mice (□) faecal 
samples collected at the end of the experiment. 
 
4.1.4.3 Tumour immune infiltrate analysis in FMT mice 
Tumour specimens from FMT-mice were analysed by IHC to characterize immune 
cells infiltration (Fig. 4.14). No significant differences were found in the number of CD45+ 
cells among groups (Fig. 4.14 A), while a significant decrease in CD3+ cells was observed 
in mice transplanted with faecal material from streptomycin-treated mice but not in FMT-
vancomycin (Fig. 4.14 B). Similar to previous observation in antibiotic-treated mice, an 
increment in myeloid infiltrate in FMT-antibiotic mice tumours was observed (Fig. 4.14 
C), supporting the hypothesis that antibiotic-associated microbiota composition promoted 
immunosuppressive tumour microenvironment. Furthermore, the intratumoral CD4+ T 
cells and GZMB+ cells increased upon trastuzumab treatment only in mice reconstituted 
with faeces from control donors (FMT-NoA) (Fig. 4.14 D-E) while the trend towards the 
increment of GMZB+ cells noted in FMT-streptomycin mice may explain the partial 
response to trastuzumab observed in these mice. These results confirm the relevance of 
CD4+ T lymphocytes and GZMB+ cells for trastuzumab efficacy and point out the direct 
involvement of the gut microbiota in the modulation of tumour immune microenvironment.  
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Figure 4.14 Analysis of immune infiltrate in tumours from FMT-mice. 
Characterization of immune infiltrate in tumours from FMT-mice. A-C) Count of total 
CD45+ (A), CD3+ cells (B), Gr-1+ cells (C). D-F) Intratumor and stromal staining of 
CD4+ T cells (C), and granzyme B (GZMB) positive (D) cells. Intratumor (white) and 
stromal (gray). (Data shown as box-and-whiskers, min to max) * p<0.05; **p< 0.01 and 
***p<0.001 by unpaired Student’s t-test. 
 
4.1.5 Impact of gut microbiota on trastuzumab efficacy in a model of spontaneous 
HER2-positive breast cancer 
The human HER2 receptor has been widely demonstrated to have immunogenic 
properties,  and  the possibility of HER2 to elicit an immune response cannot be ruled out. 
Thus, the impact of antibiotic-induced modification of gut microbiota was investigated in 
FVB ∆16HER2 transgenic mice (∆16HER2), a model of spontaneous mammary gland 
tumorigenesis {Marchini, 2011} tolerant for the HER2 antigens, to exclude that the 
immunogenicity of the human HER2 receptor could have limited the interpretation of the 
results obtained so far in the FVB transplantable model. In this model, female mice start to 
develop mammary lesions from the age of eight-weeks and tumours became palpable 
approximately between the 12
th
-14
th
 week. 
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To study the impact of gut microbiota alteration on tumour growth and trastuzumab 
efficacy, female Δ16HER2 transgenic mice were fed vancomycin in the drinking water 
immediately after weaning and the consequence of vancomycin administration on 
trastuzumab efficacy was assessed in two different treatment schedules. In first case, 
trastuzumab was administered to mice starting from the age of eight-weeks, when only 
intraepithelial lesions are present and all tumour cells rely on HER2 expression to grow 
(Fig. 4.15). The treatment was then continued for 10 weeks and the ability of trastuzumab 
to inhibit tumours development (Fig. 4.15 A) and multiplicity (Fig. 4.15 B) was similar 
between the two groups.  
Figure 4.15 Antitumor efficacy of trastuzumab in vancomycin-treated Δ16HER2 
mice. Female FVB mice were given vancomycin (200 mg/L) in the drinking water 
immediately after weaning. Mice were treated with trastuzumab (8 mg/kg body weight) 
once a week for 10 weeks. The efficacy of trastuzumab was evaluated by recording the (A) 
onset (p=0.009 by Log-rank test) and (B) multiplicity of spontaneous tumours developed in 
the different experimental conditions.  
 
Further, to examine the consequences of vancomycin administration on the 
therapeutic efficacy of trastuzumab rather than its preventive benefit, the experiment was 
repeated treating mice with trastuzumab when a palpable tumour burden (almost 3 mm of 
diameter) was developed, a condition that is more similar to the one observed in patients. 
In this case, the inhibition of tumour growth was more effective in control mice as 
compared to vancomycin-treated mice (Fig. 4.16 A) while it was confirmed that 
vancomycin did not affect tumour onset (Fig. 4.16 B) and multiplicity (Fig. 4.16 C).  
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These results showed that the inhibition of HER2 during the early stages of tumour 
development is enough to block tumour growth, probably due to cancer cells addiction to 
HER2 signalling, independently from host conditions such as gut microbiota perturbation 
or tolerance to the HER2 immunogenic antigen. On the contrary, tumour cells extrinsic 
factors, such as gut microbiota, can impact trastuzumab therapeutic efficacy in later stage 
of tumour growth. 
 
Figure 4.16 Therapeutic efficacy of trastuzumab in vancomycin-treated Δ16HER2 
mice. A) Trastuzumab efficacy in female Δ16HER2 transgenic FVB mice treated or not 
with vancomycin (200 mg/L). After the first tumour onset mice were treated with 8 mg/kg 
of trastuzumab once a week for 6 weeks. Reported is the growth curve of the first tumour. 
The antibody anti-tumour efficacy was assessed by measuring tumour growth (Black, 
tumour growth in control mice; red, tumour growth in mice treated with trastuzumab). B-
C) Tumour onset (B) and multiplicity (C) in female Δ16HER2 transgenic FVB mice 
treated with vancomycin. * p<0.05 and **p< 0.01 by unpaired Student’s t-test. 
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4.1.6 Administration of lactic acid bacteria to improve trastuzumab efficacy 
To explore the possibility to use lactic acid producing bacteria (LAB) to improve the 
antitumor efficacy of trastuzumab, two strains of LAB were used in vancomycin-treated 
mice. In fact, in addition to the strong decrease in the levels of total lactate found in faeces 
of antibiotic-treated mice, LAB are well known for their probiotic properties.  Lactococcus 
lactis and Lactobacillus paracasei were orally administered three times a week to FVB 
female mice bearing MI6 tumours that were under vancomycin regimens. The treatment 
with the probiotic increased the inhibition of tumour growth by trastuzumab in mice under 
vancomycin regimen (Fig. 4.17).  
Figure 4.17 Impact of LAB on trastuzumab efficacy in vancomycin-treated mice. 
Vancomycin-treated FVB mice bearing MI6 tumours received 200 µL of bacteria 
suspension (1x10
9 
Lactococcus lactis or Lactobacillus paracasei) three times a week 
throughout the entire experiment. Trastuzumab was administered twice a week at a 
concentration of (5 mg/kg body weight) starting when tumours reached a palpable volume. 
Trastuzumab efficacy was measured in terms of tumour growth inhibition in control mice 
(A) and vancomycin-treated animals (B). * p<0.05;  ** p<0.01 and *** p<0.001 by 
unpaired Student’s t-test. 
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were also analysed and besides a trend in the reduction of their frequencies in control 
animals upon trastuzumab administration, no significant modulations were observed (Fig. 
4.18 E-F). 
Further investigation should be performed to clarify the role of LAB in trastuzumab 
activity and elucidate the mechanisms underlying their positive influence on the mAb 
efficacy. 
 
Figure 4.18 Immune characterization of tumours from LAB treated mice. Flow 
cytometry analysis of tumour immune infiltrate in LAB-treated mice. A-F) Frequencies of 
immune subpopulation are displayed: CD3+ lymphocytes T (A), CD4+ T lymphocytes in 
CD3+ cells (B), CD8+ T lymphocytes in CD3+ cells (C), NK cells gated on CD3 negative 
and CD49b + cells (D), CD11b+ myeloid cells (E), macrophages, F4/80+ cells in CD11b+ 
population (F). 
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4.2 Gut microbiota and anti-HER2 efficacy in the BALB/c murine model  
To validate the results obtained so far in a different murine model of HER2-positive 
BC, two different cell lines were tested in BALB/c mice: D2F2/E2 and TUBO. The mouse 
mammary tumour line D2F2/E2 derived from a spontaneous mammary tumour grown in 
BALB/c mice (D2F2) and transfected to overexpress the human HER2 receptor protein 
{Piechoki, 2001}. TUBO cells were established from spontaneous mammary tumour in 
BALB/c-neuT transgenic mouse {Rovero, 2000} that overexpress the mutated rat neu 
antigen which is homologous to the human HER2 receptor. To test the sensitivity of these 
two cell lines to the anti-HER2 treatment, D2F2/E2 and TUBO cells were tested in vivo 
(Fig. 4.19). Mice bearing D2F2/E2 tumours received trastuzumab twice a week but no 
inhibition of tumour growth was observed. Conversely, the treatment with the 7.16.4 mAb, 
antibody specific for the rat neuT antigen, in BALB/c mice bearing TUBO tumours 
significantly reduced the tumour growth. Based on these results, to study the impact of 
antibiotic on HER2 inhibition in BALB/c mice TUBO cell line was used.  
 
Figure 4.19 Tumour growth and anti-HER2 treatment in two BALB/c models.  A) 
BALB/c mice bearing D2F2/E2 tumours were treated with trastuzumab (5 mg/kg body 
weight)  twice a week starting when tumour reached a palpable volume. B) BALB/c mice 
bearing TUBO tumours and treated with the anti-HER2 mAb 7.16.4 (100 µg/mouse) twice 
a week for two weeks. The efficacy of the anti-HER2 treatment was evaluated in terms of 
tumour growth inhibition. Black: untreated; red: anti-HER2 treated mice. * p<0.05; ** 
p<0.01 and *** p<0.001 by unpaired Student’s t-test. 
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4.2.1 Impact of antibiotic-induced microbiota modification on 7.16.4 mAb efficacy 
4.2.1.1 Efficacy of anti-HER2 treatment in antibiotic-treated and FMT BALB/c mice  
Vancomycin or streptomycin were administered in the drinking water of four-weeks 
old BALB/c mice for the entire duration of the experiment and TUBO cells were injected 
into the mammary fat pad after four weeks from the beginning of antibiotic treatment. The 
efficacy of the mAb 7.16.4 was assessed by treating animal twice a week for two weeks 
with 100 µg of mAb upon the establishment of a palpable tumour burden. In contrast to 
what observed in FVB mice bearing MI6 tumours, antibiotic administration did not impact 
the inhibition of tumour growth in 7.16.4 treated mice (Fig. 4.20 A). The same result was 
obtained in mice transplanted with faeces of antibiotic-treated donor mice. As observed in 
donor mice the anti-HER2 7.16.4 mAb equally inhibited tumour growth in both FMT-
control and FMT-antibiotic mice (Fig. 4.20 B). 
 
Figure 4.20 Efficacy of anti-HER2 treatment in BALB/c mice under antibiotic 
treatment. A) Tumour growth measurement in control mice (no-antibiotic, NoA) or mice 
under vancomycin, or streptomycin treatment (200 mg/L) B) Tumour growth measurement 
in FMT-mice. Six-weeks old BALB/c mice were treated daily for 10 consecutive days with 
200 µL of ABX (vancomycin 5 mg/mL, neomycin, metronidazole and ampicillin 10 
mg/mL) via oral gavage to deplete their intestinal microbiota. The gut microbiota was then 
reconstituted by FMT  using stool suspension from A. Mice received biweekly the mAb 
7.16.4 (100 µg /mouse) starting when tumour reached a palpable volume for two weeks 
and antitumor efficacy was assessed by measuring tumour growth. Untreated (black) and 
7.16.4 mAb (red). * p<0.05; ** p<0.01 and *** p<0.001 by unpaired Student’s t-test.  
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4.2.1.2 Analysis of intestinal microbiota composition 
Stool samples were collected before the beginning of the anti-HER2 treatment and 
the content was analysed by 16S rRNA gene sequencing (Fig. 4.21). Similar to FVB mice, 
vancomycin had the strongest impact causing an evident decrease in the α-diversity as 
shown by the Chao1, Shannon, Simpson indexes (Fig. 4.21 A). As shown in figure 4.21 
(Fig. 4.21 B), upon vancomycin administration a reduction in the relative abundances of 
the families of Rikenellaceae, Porphyromonadaceae, Bacteroidaceae, and S24-7 was 
found concomitantly to an expansion of bacteria belonging to the phyla of Proteobacteria 
and Verrucomicrobia. Furthermore, a common reduction in the abundance of 
Lachnospiraceae and Ruminococcaceae was commonly found in the gut microbiota of 
mice under streptomycin and vancomycin treatment, two families that belong to the 
Clostridiales  order.  
 
Figure 4.21 Antibiotic-induced changes in the gut microbiota of BALB/c mice. 
Analysis of gut microbiota composition by 16S rRNA gene sequencing of faeces from 
control mice (NoA) and mice fed drinking water containing vancomycin, or streptomycin 
(200 mg/L). A-B) Microbial α-diversity between NoA and vancomycin or streptomycin 
treated mice calculated by Chao1, Shannon and Simpson indexes. B) Comparison of 
bacterial genus abundance between the three groups of treatment. *p<0.05, **p<0.01 and 
***p< 0.001 by unpaired Student’s t-test. 
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4.2.2 Influence of gut microbiota depletion on tumour immune infiltrate and anti-
HER2 treatment 
4.2.2.1  Characterization of tumour immune infiltrate in BALB/c mice  
During my six-months visit to the laboratory of Dr. Romina Goldszmid at the 
National Institute of Health (NIH), Bethesda Maryland, the immune infiltrate of TUBO  
tumours was analysed by flow cytometry in mice treated with vancomycin or ABX. 
Vancomycin (200 mg/L) was administered in the drinking water of mice for 4 weeks 
before TUBO cells injection into the mammary fat pad, in parallel a different group of 
mice were treated with the antibiotic cocktail routinely used to study the impact of gut 
microbiota on antitumor immunity in the hosting laboratory: vancomycin (500 mg/L) 
neomycin (700 mg/L) and Primaxin (500 mg/L) {Iida, 2013}. Tumours were harvested 
after two weeks from injection and single cell suspension were analysed by flow cytometry 
(Fig. 4.22) in order to study the priming effect of commensal bacteria on tumour immunity. 
No significant differences in tumour volume were observed among control and antibiotic 
(vancomycin and ABX) treated mice (Fig. 4.22 A), while ABX but not vancomycin caused 
a decrease in the frequency of CD45+ cells within the tumours (Fig. 4.22 B).  
 
Figure 4.22 Analysis of the tumour immune infiltrate in antibiotic-treated BALB/c 
mice. Antibiotics were dissolved in the drinking water: vancomycin was given at a 
concentration of 200 mg/L, while the ABX cocktail contained vancomycin (500 mg/L), 
neomycin (700 mg/L) and Primaxin (500 mg/L). After four weeks, 5x10
5 
TUBO cells were 
injected into the mammary fat pad of mice and let grow for two weeks. A) Tumour 
volumes at the time of the harvest. B) Frequencies of CD45+ cells in live cells as analysed 
by flow cytometry. *p<0.05 by Student’s t-test. 
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To characterize the immune infiltrate, markers of the lymphoid and myeloid lineage 
were used, and immune subpopulation were selected in CD45+ live cells.  No differences 
were found in the tumour microenvironment of mice whose intestinal microbiota was 
altered by the treatment with vancomycin while evident modifications were observed in the 
ABX group. The disruption of the intestinal microbiota resulted in altered infiltration of 
both lymphoid (Fig. 4.23) and myeloid (Fig. 4.24) cells in the tumours. The frequencies of 
T lymphocytes (TCRβ+ cells) and γδ T cells were decreased, and the ABX treatment 
associated with a decreased frequency of CD4+ T cells within the tumour, in particular a 
prevalence of naïve CD4+ T cells was observed in ABX-treated mice as compared to the 
control (Fig. 4.23 A-C) and vancomycin groups, characterized by a higher amount of 
memory T cells. This evidence was supported by a reduced percentage of CD44+ CD62L- 
cells in the tumour of ABX mice (Fig. 4.23 D) and the lower CD44 but higher CD62L MFI 
in this group than in the controls (Fig. 4.23 E-F). No significant differences were observed 
in CD8+ T cells and B (CD3neg CD19+) cells (Fig. 4.23 G-H). The treatment with the 
ABX also impaired tumour infiltration by NK (CD49b+NKp46+) cells (Fig. 4.23 I).  
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Figure 4.23 Characterization of lymphoid tumour infiltrate by flow cytometry. A-
D,G-I) Frequency of lymphoid cells gated on CD45+ live cells: T lymphocytes (A); γδ T 
cells  (B); CD4+ T cells (C); memory T CD4+ cells (CD44+CD62neg in CD4+) (D); 
CD8+ T lymphocytes; CD19+ B lymphocytes (H); NK cells (CD49b+NKp46+) (I). E-F) 
Median fluorescence intensity of CD44 and CD62L expression in CD4+ T cells. Cell 
frequency is represented as the percentage of positive cells in the CD45+ population. 
*p<0.05; **p<0.01; ***p<0.001 by unpaired Student’s t test. 
 
Modulation of the myeloid compartment was also found as regard to the percentage 
of neutrophils and monocytes infiltration. The depletion of intestinal microbiota was 
associated with an increase in the frequency of neutrophils (Ly6G+ cells) in the tumour 
and a concomitant reduction in the percentage and number of infiltrating monocytes 
(Ly6C
high 
cells) (Fig. 4.24 A-B). The treatment with the antibiotics also contributed to 
create an immunosuppressive tumour microenvironment by promoting the infiltration of 
M2-like macrophages, as suggested by the increased frequency of the F4/80+CD206+ 
subpopulation (Fig. 4.24 C). In addition, tumours from the ABX group were characterized 
by a reduced infiltration of DCs (Fig. 4.24 D). 
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Figure 4.24 Characterization of myeloid tumour infiltrate by flow cytometry. A-D) 
Frequency neutrophils (Ly6G+ cells) (A); monocytes (Ly6C
high
) (B); M2-like macrophages 
(F4/80+CD206+) (C); dendritic cells (DCs, CD11c+MHCII+CD24+) (D). Cell frequency 
is represented as the percentage of positive cells in the CD45+ population. *p<0.05; 
**p<0.01 by unpaired Student’s t test. 
 
4.2.2.2  Efficacy of the anti-HER2 treatment in ABX-treated mice 
Based on the different impact of ABX and vancomycin on tumour immune cells, and 
the promotion of an immunosuppressive microenvironment, the efficacy of the mAb 7.16.4 
was investigated in this model. The ABX cocktail containing vancomycin (500 mg/L), 
neomycin (700 mg/L) and ampicillin (1 g/L) to deplete intestinal microbiota was 
administered in the drinking water of mice. After four weeks of ABX treatment, TUBO 
cells were injected into the mammary fat pad as already described and when tumours 
reached a palpable volume mice received 100 µg of the 7.16.4 mAb twice a week for two 
weeks. In line with previous observation in BALB/c animals, ABX had no consequences 
on tumour growth and, as found in single-antibiotic experiment, the efficacy of the mAb 
7.16.4 was not affected by the depletion of intestinal microbiota in mice (Fig. 4.25).  
These results suggest that TUBO cells depend on the oncogenic signalling of 
HER2/neu to grow, and its inhibition with the anti-HER2 mAb 7.16.4 is sufficient to 
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inhibit tumour growth independently of the gut microbiota composition/depletion and its 
modulation of the tumour immune microenvironment.  
Figure 4.25 Anti-HER2 mAb efficacy in ABX-treated mice. BALB/c mice were treated 
with antibiotic cocktail (vancomycin 500 mg/L, neomycin 700 mg/L and ampicillin 1 g/L) 
starting from four-weeks of age. After 28 days of treatment TUBO cells were injected into 
the mammary fat pad and the treatment with 7.16.4 was started when tumour reached a 
palpable volume. mAb was administered twice a week for two weeks. **p<0.01; 
***p<0.001 by unpaired Student’s t test. 
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4.3 Gut microbiota and trastuzumab-based therapy in HER2-positive BC patients 
4.3.1 Trastuzumab benefit and gut microbiota composition 
4.3.1.1 Clinical characteristics of HER2-positive BC patients 
To assess the clinical relevance of our findings, the association between intestinal 
microbiota composition and trastuzumab benefit was investigated in HER2-positive BC 
patients treated with neoadjuvant trastuzumab-based chemotherapy. The study was 
performed in collaboration with Dr. Fabio Corsi from the Dept. of Breast Surgery at the 
Istituti Clinici Scientifici Maugeri Spa-SB of Pavia between 2017 and 2019. Women 
received four cycle of cyclophosphamide and anthracycline-based (AC) treatment followed 
by four to six cycles of taxanes and trastuzumab (TH) before surgery, two of them received 
TH since the beginning for six cycles. Tumour biopsies and faecal samples were collected 
from patients at diagnosis and before the beginning of trastuzumab treatment respectively 
(Fig. 4.26).  
 
Figure 4.26 Samples collection from HER2-positive BC patients. Tumour biopsy and 
stool samples were collected at diagnosis and before trastuzumab treatment respectively. 
Gene expression profile (GEP) was performed on available tumours and the gut microbiota 
composition was analysed by 16S rRNA gene sequencing. 
 
Patients who achieved pCR and were considered responsive (R) while those with 
breast residual disease at the time of the surgery were classified as non-responders (NR), 
clinical information of patients enrolled in the study are summarized in table 4.1. No major 
differences in patients characteristics were observed in R versus NR except for the lymph 
nodes status (N) with 43% versus 10% of N+ patients in NR and R, respectively (Table 
4.2).  
Surgery
AC TH
GEP analysis
Tumour 
biopsy 
Faeces 
collection
16S sequencing
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Table 4.1 Clinical information of the patients enrolled in the study. 
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Table 4.2 Clinicopathological variables of the analysed patients  
 
 
pCR NR p-value* Cluster 1 Cluster 2 p-value* 
Age (years) 
 Median (range)  51 (41-71)    59 (41-76) 
0.1467╪ 
 
62 (41-76) 
 
53 (41-71) 
0.2227╪ 
Tumour size  
 
  1.00   1.00 
 ≤ 2 cm 5 (45%) 3 (43%) 
 
3 (50%) 5 (42%)  
 >2 cm 6 (55%) 4 (57%)  3 (50%) 7 (58%) 
 
Lymph node status   
 
 0.0474      1.00 
Negative (N-)     1 (16%)   4 (57%) 
 
2 (33%) 3 (25%)  
Positive (N+)   10 (84%)   3 (43%) 
 
4 (67%) 9 (75%)  
ER status 
 
  1.00   1.00 
Negative     4 (47%)   2 (29%) 
 
2 (33%) 4 (33%)  
Positive    7 (53%)   5 (71%) 
 
4 (67%) 8 (67%)  
PR status  
 
 0.3156         0.60 
Negative    5 (45%)   1 (14%) 
 
1 (17%) 5 (42%)  
Positive   6 (55%)    6 (86%) 
 
5 (83%) 7 (58%)  
Grade  
 
  1.00     1.00 
I and II   5 (45%)   4 (57%)  
 
3 (60%) 6 (50%)  
III    6 (50%)   3 (43%)  
 
2 (40%) 6 (50%)  
PAM50 
   
   
HER2-E 
Others 
6 (75%) 
2 (25%) 
4 (80%) 
1 (20%) 
      1.00 
 
4 (80%) 
1 (20%) 
6 (75%) 
2 (25%) 
  1.00 
ER, oestrogen receptor; PR, progesterone receptor; pCR, pathological complete response; NR, non-
responsive; HER2-E, HER2-enriched.
*
, p-value of the Fisher exact test. 
╪
, p-value of the Mann-Whitney test 
 
4.3.1.2 Analysis of the gut microbiota composition in HER2-positive BC patients 
To evaluate whether commensal bacterial composition associated with clinical 
benefit of trastuzumab the DNA was extracted from faecal samples of 18 HER2-positive 
BC patients collected before the beginning of trastuzumab treatment and the 16S rRNA 
gene was profiled. The α-diversity between patients was analysed by using Chao1, 
Shannon and Simpson indexes and a trend towards significant higher diversity in R 
compared to NR patients was observed (Fig. 4.27 A). The PCoA of intestinal ecology β-
diversity revealed a clustering effect between R and NR patients showing a possible 
association between microbiota characteristics and response to trastuzumab (Fig. 4.27 B).  
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Figure 4.27 Metagenomic analysis of faecal samples from HER2+ BC patients. The 
composition of the gut microbiota was analysed in 18 HER2-positive BC patients treated 
with neoadjuvant trastuzumab-based chemotherapy. A) Analysis of α-diversity between R 
(n=11) and NR (n=7). Microbial α-diversity was calculated by different indexes (i.e. 
Chao1, Shannon and Simpson indexes). B) Analysis of β-diversity between R (green) and 
NR (red). Principal coordinate analysis for microbial was generated using weighted 
UNIFRAC distance. 
 
To identify differentially abundant bacteria between patients who benefitted or not 
from trastuzumab treatment, data obtained from the 16S rRNA gene profiling was 
analyzed by LEfSe. Patients who achieved pCR were characterized by a microbiota 
enriched in bacteria from the Clostridiales taxonomic orders while Bacteroidales were 
more abundant in NR then R. Specifically, members from the taxonomic families 
Lachnospiraceae, Turicibacteriaceae, Coriobacteriaceae and Prevotellaceae were less 
represented in NR patients, as observed in animals upon antibiotic treatment, suggesting 
their possible role in favouring the response to trastuzumab (Fig. 4.28 A-B).  
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Figure 4.28 Differences in bacterial community according to patients response. A) 
Linear discriminant analysis (LDA) scores computed for differentially abundant taxa in the 
faecal microbiomes of R (green) and NR (red). Length indicates effect size associated with 
a taxa. B) Taxonomic cladogram from LEfSe showing differences in faecal taxa. Dot size 
is proportional to the abundance of the taxa.  
 
When the content of SCFAs was analysed in stool samples from 11 HER2+ BC 
patients (7 R and 4 NR), a trend towards a reduction of acetate, propionate and butyrate, 
but not lactate, was observed in NR patients despite the low number of samples and the 
high variability detected (Fig. 4.29).   
 
 
 
A B
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Figure 4.29 SCFAs and lactate 
quantification in HER2-positive BC patients. 
Products of bacteria metabolism were analysed 
in faecal samples collected before trastuzumab 
treatment in R (green) and NR (red). The 
analysis was performed by ultraperformance 
liquid- chromatography-high resolution-mass-  
spectrometry analysis (UPLC-HR-MS) for 
SCFAs and by enzymatic kit for lactate.  
 
4.3.1.3 Causal role of the gut microbiota in HER2-positive BC patients treatment. 
The causal link between a “favourable” gut microbiota and the response to 
trastuzmab was assessed by transferring faecal material from R (n=6) and NR (n=4) 
patients into recipient mice (Fig. 4.30 A). Notably, R-FMT mice benefitted from the anti-
HER2 treatment in contrast to NR-FMT mice confirming the direct involvement of 
commensal bacteria in trastuzumab efficacy (Fig. 4.30 B). 
 
Figure 4.30 Human commensal bacteria modulate trastuzumab antitumor efficacy in 
mice. A) FVB mice were depleted from their intestinal microbiota using ABX cocktail and 
were then gavages with faecal material from responsive patients (R, n=6) and non-
responders (NR, n=4). Faecal material was transplanted 48h before and after tumour cells 
injection and then every 10 days for a total of 5 FMT (7-8 mice/patients were used). 
Trastuzumab (5 mg/kg body weight) was administered twice a week for three weeks  
starting when tumours reached palpable volumes B-C) Tumour weight measurement 
evaluated at the end of the experiment (B). **p<0.01 by unpaired Student’s t test. 
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4.3.2 Predictive potential of commensal bacteria composition in neoadjuvant treated 
HER2-positive BC patients 
To investigate the potential use of the gut microbiota as a predictive biomarker, an 
unsupervised clustering analysis was applied to patient’s β-diversity and two clusters 
separate patients according to trastuzumab response (silhouette=0.33 ) (Fig. 4.31 A): 71% 
(5/7) of NR patients segregated in cluster 1 and 91% (10/11) of R gathered together in 
cluster 2. The two clusters significantly associated with response to trastuzumab as 
analysed by Fisher’s exact test (p=0.0128). Based on the relevance of tumour intrinsic 
characteristics in discriminating patients sensitive or not to trastuzumab, the PAM50 
subtype predictor was applied to GEP of tumour core biopsies available for 13 out of 18 
patients. The HER2-enriched tumours, defined as the most responsive to trastuzumab, were 
found in both the microbiota clusters (4/10 in cluster 1 and 6/10 in cluster 2) (Fig. 4.31  
and table 4.2), indicating that gut microbiota may have the potential to join further 
information to HER2-enriched BC subtype in identifying R or NR patients. 
Figure 4.31 Association between gut microbiota and response to the anti-HER2 
treatment. The unsupervised clustering was performed by applying the JSD algorithm to 
the β-diversity analysis derived from weighted UniFrac algorithm: Cluster 1 (5 NR + 1 R) 
and Cluster 2 (2 NR + 10 R) associated with the response to trastuzumab as evaluated by 
Fisher’s exact test (p=0.0128). Tumour intrinsic subtypes defined by PAM50 molecular 
classifier are displayed as (□) HER2-enriched tumours, (O) basal tumours, (∆) tumours 
whose GEP was not available. 
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Chapter 5: DISCUSSION 
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The introduction of trastuzumab (Herceptin) in the clinical use has largely improved 
the clinical outcome of early, advanced and metastatic HER2-positive patients. 
Nonetheless, a high number of women receiving trastuzumab do not benefit from this 
treatment and the reasons underlying the heterogeneous response observed in patients still 
need to be fully comprehend. Moreover, studies focused on the development of response 
predictors that are based on tumour characteristics still miss a high number of patients that 
do not benefit from trastuzumab. This evidence and the fact that even the double-block of 
the HER2 receptor did not completely remove the presence of resistant patients, moved 
researchers to consider extrinsic tumour factors that could be involved in trastuzumab 
efficacy. Preclinical and clinical evidence unravelled the influence of the gut microbiota on 
anticancer therapies that rely on immune activation for their activity, and since 
trastuzumab can be considered an immunomodulatory drug, in this project, the impact of 
commensal bacteria on its antitumor activity was investigated in in vivo experiments using 
models of HER2-positive breast cancer and in patients that received neoadjuvant 
trastuzumab-based therapy.  
Firstly, the involvement of gut commensal bacteria in the therapeutic efficacy of 
trastuzumab was unravelled by changing the intestinal bacteria ecosystem by the 
administration of vancomycin and streptomycin that resulted in the complete abrogation of 
tumour growth inhibition by trastuzumab in FVB mice. So far, the manipulation of the gut 
microbiota by  antibiotics, has been widely used by researchers to demonstrate the 
relevance of commensals in the anticancer efficacy of chemotherapeutic drugs such as 
doxorubicin, and cyclophosphamide{Viaud, 2015} and of immunotherapy (i.e. anti-
PD1{Routy, 2018a}), anti-CTLA4 {Vétizou, 2015} and anti-IL10R{Iida, 2013}). Despite 
the different mechanisms of action of vancomycin, mainly directed against Gram-positive 
bacteria {Hammes, 1974} and streptomycin, a broad spectrum protein synthesis inhibitor 
{Demirci, 2013}, the two antibiotics equally inhibited trastuzumab efficacy suggesting that 
111 
 
the gut community structure significantly affected the response to therapy. While 
vancomycin robustly reduced α-diversity and caused a wide decrease in the abundances of 
bacterial taxa belonging to Bacteroidetes and Firmicutes taxonomic phylum with a parallel 
over-representation of Proteobacteria and Verrucomicrobia, streptomycin mainly affected 
the relative abundance of bacteria in the Firmicutes phylum. Within the phylum 
Firmicutes, both antibiotics determined the reduction of numerous taxa belonging to the 
order of Clostridiales, and particularly to the Lachnospiraceae family and SCFA-
producing taxa like Ruminococcaceae and Lachnospiraceae (together with the 
Odoribacter genus in the Bacteroidales taxonomic order) that can explain the decrease in 
the level of butyrate, propionate and acetate observed in antibiotic treated mice. These 
products of bacterial fermentation are usually exploited by intestinal epithelial cells as a 
source of ATP but they can also have important immunomodulatory function as for 
instance butyrate, by activating the GCPRs on IECs and immune cells, favours the 
maintenance of the gut barrier inhibiting the inflammatory responses in human monocytes 
{Parada Venegas, 2019}. SCFAs represent the connection between intestinal ecology and 
systemic immunity and may be the key to overcome the difficulties related to the 
microbiota therapeutic intervention being exploited to improve anticancer treatment 
efficacy in future. To investigate these aspects, SCFAs levels were quantified in the blood 
of mice and their amount resulted to be lower in antibiotic-treated animals than in controls 
indicating that gut conditions can be reflected systemically even though we are aware that 
these results should be considered with caution due to the <LOQ quality of our samples. 
When the tumour immune microenvironment was analysed, major differences were 
found upon trastuzumab administration but not at basal levels, in fact trastuzumab induced 
a spatial redistribution between stroma and tumour nests of CD4+ T lymphocytes and 
GZMB+ cells in tumours of control animals but not in tumours of mice under vancomycin 
or streptomycin treatment. Coherently, the relevance of T lymphocytes and NK cells was 
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supported by the analysis of the expression levels of Il12a and Il15, , two proinflammatory 
cytokines required for proliferation and activation of Th1 lymphocytes and NK cells, that 
were found to be  higher in control than in vancomycin or streptomycin mice treated with 
trastuzumab. These findings are in line with published data by which alteration of the gut 
microbiota have been reported to negatively impact immune cells activation in response to 
cancer treatment (i.e. CpG oligonucleotide and oxaliplatin {Iida, 2013} or anti-CTLA4 
{Vétizou, 2015}). Moreover, the analysis of the intratumoral cytokines expression showed 
higher levels of il15 in vancomycin- and streptomycin-treated animals than control. IL-15 
is produced by macrophages and it is involved in the activation of NK cells and CD8+ T 
cells with the potential to enhance the antitumor activity of trastuzumab when used in 
combination {Wege, 2017}. However, the continuous stimulation with IL15 can cause NK 
cells exhaustion {Felices, 2018} that may explain why mice under antibiotic regimen did 
not benefit from trastuzumab treatment. Based on higher number of Gr-1 and Arg1 positive 
cells and on higher tgfb1 expression levels in tumours from antibiotic-treated than control 
mice, we can hypothesise the development of a suppressive immune microenvironment in 
antibiotic-treated mice. Starting from these observations, further experiments will be 
essential to deeper investigate the mechanisms by which trastuzumab is influenced by 
commensal bacteria and whether the modulation of tumour microenvironment directly 
depends on gut microbiota.  
Surprisingly, different results were obtained in a second transplantable model of 
HER2-positive breast cancer in BALB/c mice: vancomycin and streptomycin 
administration did not impact the efficacy of the anti-HER2 mAbs 7.16.4 against the 
growth of TUBO tumours although the antibiotic-induced modifications of the gut 
microbiota were similar to the one observed in FVB mice. Further investigation in the 
BALB/c model revealed that the depletion of the intestinal microbiota by ABX had a 
strong consequences on the tumour immune infiltrate lowering frequencies and numbers of 
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immune cells such as NK cells, CD4+ T cells, DCs and macrophages, accompanied by an 
increase in neutrophils and CD206+ macrophages with potential suppressive properties. 
Nonetheless, even the establishment of a pro-tumorigenic immune phenotype was not 
enough to affect trastuzumab antitumor efficacy suggesting that in TUBO cells, which 
overexpressed the mutated human homologue HER2/neu receptor, the inhibition of HER2 
signalling is sufficient to inhibit tumour growth in an immune-/microbiota-independent 
mechanism. Likely, the gut microbiota plays a relevant role especially in those tumour in 
which the efficacy of the anti-HER2 treatment relies the most on the engagement of 
immune cells to inhibit tumour growth, while it has a marginal, or even no role, in those 
tumours completely dependent on the HER2 intracellular signalling. In support to this 
hypothesis, the modification of gut microbiota by vancomycin did not affect the efficacy of 
trastuzumab FVB Δ16HER2 transgenic mice when the treatment was started before tumour 
onset when only intraepithelial lesions are present and the proliferation of tumour cells is 
dependent from the Δ16HER2 receptor. The vancomycin-impairment of trastuzumab 
efficacy, was only observed when trastuzumab was administered in Δ16HER2 mice with 
already established tumours supporting the role of gut microbiota in the immune-mediated 
efficacy of trastuzumab. Furthermore, vancomycin treatment had no consequences on 
tumour onset and multiplicity in FVB Δ16HER2 mice differently from previously 
published results in which antibiotic administration associated with increased development 
of mammary gland tumours {Rossini, 2006} in Proto-neu transgenic mice. 
The consistency between the results obtained in both spontaneous and transplantable 
FVB model suggests that the interpretation of the data was not limited by the immunogenic 
potential of HER2, in fact an immune response elicited agaist the HER2 antigen in the 
transplantable tumour model could have concealed the influence of gut microbiota on the 
immune-mediated activity of trastuzumab.  
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It is possible that antibiotic treatment can have a direct cytotoxic effect on tumours as 
some of them are reported to inhibit proliferation in human mesenchymal stem cells 
{Bariteau, 2018} osteoblasts {Eder, 2016} and glial cells {Sofian, 2012}. Thus, although 
vancomycin and streptomycin are characterized by a poor adsorption in the intestine, a 
systemic effect of the antibiotic on tumour cells cannot be ruled out. However, the analysis 
of HER2 expression and modification of the tumour microenvironment, excluded the 
negative impact of antibiotics on trastuzumab distribution within the tumours and on its 
binding to HER2, two possible reasons for a less effectiveness of trastuzumab. 
The direct link between gut microbiota and trastuzumab efficacy was demonstrated 
through an experiment of faecal microbiota reconstitution. The transplantation of faeces 
from control donors, but not from vancomycin donors, into ABX-treated FVB mice 
restored the efficacy of trastuzumab demonstrating the causality between commensal 
bacteria and the mAb activity in our animal model. The compromised recruitment of CD4+ 
T lymphocytes and GZMB+ cells in tumour of mice whose microbiota was reconstituted 
with faecal suspension from antibiotic-treated mice confirms the involvement of gut 
microbial ecosystem in trastuzumab-mediated triggering of host immune cells. Mice 
transplanted with faecal material from streptomycin-treated donors reproduced only 
partially the donor phenotype: besides an initial inhibition of trastuzumab activity they 
ended responding to the treatment. This is at least in part explained by the similarities 
between the gut microbiota of FMT-streptomycin mice and control mice observed at the 
end of the experiment likely due to the less severe  alteration induced by streptomycin in 
the intestinal ecology as compared to those of vancomycin. 
In this project we explored the possibility to use probiotic lactate-producing bacteria 
(LAB) to improve trastuzumab activity. In fact, in addition to a reduction in SCFAs levels, 
a common reduction in the amount of lactate in comparison to control mice was found and 
thus a beneficial potential of LAB was hypothesized. The concomitant administration of 
115 
 
Lactococcus lactis or Lactobacillus paracasei and trastuzumab improved its efficacy in 
mice under vancomycin regimens. To date, many studies reported the immune-enhancing 
activity of LAB species and strain like Lactobacillus casei Shirota has been reported to 
promote NK cells activation and Th1 immunity {Yasui, 2004}. However, no modification 
in intratumour immune cells frequencies was observed in mice gavaged with L. lactis or L. 
paracasei. This is probably due to the fact that the activation and spatial distribution of 
cells within the tumour microenvironment were not analysed and they probably would 
better reflect the impact of intestinal microbiota modification on tumour immune infiltrate 
than the simple analysis of immune subpopulation frequencies. 
To translate the results obtained in animal studies to a clinical context, the content of 
the gut microbiota was analysed in HER2+ BCs treated with trastuzumab-based therapy 
and it revealed differences in association with the clinical response. Although the small 
number of patients in our cohort, the β-diversity analysis by PCoA was able to show a 
certain grade of separation between patients who achieved pCR and those who had residual 
disease at the time of the surgery. The achievement of pCR in HER2+ BC is associated 
with long-term outcome of patients and has been proposed as a surrogate endpoint for 
prediction of long-term clinical benefit such as DFS, EFS and OS {Cortazar, 2014}. 
Several studies have demonstrated strong association of specific gut microbiome signature 
with the response to immune checkpoint blockade, showing its potential value as predictor 
of patients clinical outcome with the ability to overcome other known biomarkers {Matson, 
2018}. Together with microbiota composition, Dr Wargo’s group {Gopalakrishnan, 2018} 
found that metastatic melanoma patients responsive to the anti-PD1 treatment had 
significantly higher alpha diversity compared to NR. In addition, R melanoma metastatic 
patients also clustered separately in the analysis of β-diversity by PCoA {Matson, 2018; 
Gopalakrishnan, 2018}. In our study, patients who achieved pCR presented different 
microbiota from non-responders: a prevalence of bacteria belonging to the Clostridiales 
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order characterized the gut microbiota of R patients, while higher abundance of 
Bacteroidales was found in NR as compared to R patients. Members of the 
Lachnospiraceae, Turicibacteriaceae, Coriobacteriaceae and Prevotellaceae taxonomic 
families were found less abundant in NR patients, as observed in antibiotic-treated mice, 
implying the relevance of these bacteria for trastuzumab benefit. Bacteria belonging to 
these taxonomic families are usually associated with homeostasis of the gut and a diet 
enriched in fibre {Zhao, 2018}.  
The unsupervised clustering analysis identified two microbiota clusters that 
significantly discriminated patients according to response supporting predictive properties 
for gut communities in the treatment of HER2-positive BCs patients. Notably, when the 
PAM50 intrinsic molecular classification {Prat, 2014b} was applied to tumours, HER2-
enriched cases were distributed in the two microbiota clusters based on trastuzumab 
response, supporting the contribution of gut microbiota in trastuzumab activity 
independently of tumour intrinsic molecular characteristics. Furthermore, the capability to 
recapitulate the response observed in clinical setting in mice transplanted with faecal 
material from R and NR patients, and the association of the unsupervised clustering 
analysis with the response to the treatment suggest the potential role of the gut microbiota 
as predictive biomarker. These findings advise that the gut microbiota should be 
considered in larger studies to assess its potential as independent predictor able to add 
information in the identification of those patients who benefit the most from the 
trastuzumab-based treatment. 
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Chapter 6:CONCLUSIONS AND FUTURE 
PERSPECTIVES 
  
118 
 
In conclusion, our results demonstrate that trastuzumab antitumor activity is 
influenced by the gut microbiota composition, at least in tumours where the block of HER2 
signalling is not sufficient to completely inhibit tumour growth . In fact, an intact intestinal 
microbiota is required for the fully efficacy of this mAb likely due to the ability of gut 
bacteria to shape host immunity.  
In the FVB models, the alteration of intestinal microbiota by the use of a single 
antibiotic (vancomycin or streptomycin) abrogated the benefit of anti-HER2 treatment with 
a causal role for the microbiota. The same results were observed in FVB Δ16HER2 
transgenic mice, excluding the possibility that the presence of a strong immunogen, such as 
the human HER2, limited the interpretation of data in the syngeneic FVB transplantable 
model. Further, LAB administration was able to improve the sensitivity to trastuzumab in 
FVB under vancomycin treatment. In the BALB/c model, the single-antibiotic treatment 
and consequent intestinal microbiota modification did not impact the effectiveness of the 
7.16.4 mAb. In a similar way, the depletion of the intestinal microbiota, although affecting 
the tumour immune infiltrate did not result in a diminished efficiency of the mAb 
underlying the importance of a high sensitivity of tumour cells to the treatment 
independently of the tumour microenvironment. Ongoing experiment in preclinical model 
will help to define the mechanisms by which the gut microbiota interferes with 
trastuzumab benefit, our studies will be then focused on the modification occurred in the 
tumour immune microenvironment upon alteration of the intestinal ecosystem. This 
represents a cogent challenge to design novel therapeutic approaches, other than the 
addition of other anti-HER2 agents or immunotherapy, for patients with HER2-positive BC 
who are resistant to trastuzumab.  
In patients, despite the small number of cases, a differential microbiota abundance 
was identified between R and NR opening the possibility of using gut microbiota as 
predictive biomarkers. To validate our results in a larger cohort, we propose to enrolled 
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HER2-positive BC patients in both neoadjuvant and metastatic setting. Although determine 
the optimal sample size for our study is difficult due to the challenging statistical power 
and the unknown effect size analysis of the gut microbiota, we believe, by assuming a  
medium effect size of 0.5 for the gut microbiota on trastuzumab activity, that a minum 
number of 40 patients should be enrolled in this study to compare the proportion of 
responders and non-responders according to gut microbiota composition using two sided 
Chi-square test with a type I error of 0.05.  In addition, having a larger cohort of patients, 
will enable us to assess the association of the gut microbiota with other clinicopathological 
variables along with its predictive potential with respect to pCR evaluated through 
multivariate regression model that takes into consideration other already known 
biomarkers for trastuzumab response such as age, tumour size, nodal status, ER status and 
PAM50 classification. Particular attention will be paid for the  antibiotic usage (high 
variability in the individual time needed for the recovey from changes occurred in the 
intestinal microbiota), storage condition (long period at room temperature may favour the 
increase of some bacteria more than other) and diet. These are three main sources of 
variability that we will be considered as confounders at the time of definition of control 
and exclusion criteria. For these reasons the use of antibiotics, the time passed from 
sampling to storage at -80°C and alimentary habits will be recorded and considered in 
future analyses.  
The results obtained so far also represent the starting point to elaborate strategies 
aimed at the improvement of the therapeutic success in HER2+ BC. Interestingly, patients 
achieving pCR were characterized by high Clostridiales and low Bacteroidales relative 
abundances. Dietary interventions such as increasing the amount of fibre in the diet 
{Makki, 2018}, walnuts {Byerley, 2017}, or supplementation of prebiotic fibre {Umu, 
2017} is able to promote the growth of these bacteria in the host and it would be very 
interesting in the future to investigate the beneficial effects of dietary intervention (or 
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pre/probiotics administration) on HER2-positive BC patients outcome. In support to the 
possibility to exploit the microbiota-immune axis in trastuzumab treatment, in the past, oral 
administration of TLR2 agonist was used to improve the immune-mediated antitumor 
efficacy of trastuzumab {Lu, 2011}. Similar to the ongoing study of the Wargo’s group the 
potential benefit of a high fibre diet or the use of pre/probiotics can be investigated as an 
alternative strategy to boost the immune-mediated trastuzumab activity by fitting the gut 
microbiota composition. 
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